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INTRODUCTION 
ORAL DRUG DELIVERY SYSTEM: 
 Over the past 30 years, as the expense and complications involved in 
marketing new drug entities have increased, with concomitant recognition of the 
therapeutic advantage of controlled release drug-delivery, greater attention has 
been focused on development of sustained or controlled release drug delivery 
system. These are several reasons for the attractiveness of these dosage forms. It is 
generally recognized that for many disease states, a substantial number of 
therapeutically effective compounds already exist. The effectiveness of these 
drugs, are, is often limited by side effects or the necessity to administer the 
compound in a clinical setting. The goal in designing sustained or controlled 
delivery system is to reduce the frequency of dosing or to increase effectiveness of 
the drug by localization at the site of action, reducing the dose required or 
providing uniform drug delivery.1,2 
1.1 CONTROLED RELEASE DRUG DELIVERY SYSTEM 
 (CDDS) 
 The goal of any drug delivery system is to provide a therapeutic amount of 
drug to the proper site in the body to achieve promptly and then maintain the 
desired drug concentration. The drug-delivery system should deliver drug at a rate 
dictated by the needs of the body over a specified period of treatment. A number 
of systems containing hydrophobic and waxes were fabricated with drugs in to 
dosage forms with the aim of sustaining drug levels and hence drug action for an 
extended period of time.3 
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Terminology 
 Modified release delivery systems may be divided conveniently in to four 
categories 
1.  Delayed release 
2. Sustained release 
3. Site-specific targeting 
4.  Receptor targeting 
Delayed release 
 Delayed release systems are those that use repetitive, intermittent dosing 
of a drug from one or more immediate-release units incorporated in to a single 
dosage form.  Examples of delayed release systems include repeat action tablets 
and capsules and enteric coated tablets where timed release is achieved by barrier 
coating.4    
Sustained release 
 Sustained release systems include any drug delivery system that achieves 
low release of drug over an extended period of time sustained drug action at a 
determined rate by maintaining a relatively constant, effective drug level in the 
body with concomitant minimization of undesirable side effects. 
Site specific targeting 
 In site specific targeting, the target is adjacent to or in the diseased organ 
or tissue. 
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Receptor targeting 
           In receptor targeting, the target is the particular receptor for a drug within a 
organ or tissue. 
 
Figure 1: Plasma drug concentration profiles for conventional tablet formulation, 
a sustained release formulation and a zero order controlled release formulation. 
1.2  SUSTAINED RELEASE FORMULATIONS 
 The concept of sustained release formulation was developed to eliminate 
the need for multiple dosage regimens, particularly for those during requiring 
reasonably constant blood levels over a long period of time.  In addition, also has 
been adopted for those drugs that need to be administered in high dose, but where 
too rapid drug release is likely to cause undesirable side effects.6 
 Formulation methods used to obtain the desired drug availability rate in 
sustained action dosage forms include 
1.  Increasing the particle size of the drug 
2.  Embedding the drug in a matrix 
3.  Coating the drug or dosage form containing the drug 
4.  Forming complexes of the drug with materials such as ion exchange resins. 
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Advantages of sustained release drug delivery system 
• Improved patient convenience and compliance due to less frequent drug 
 administration 
• Reduction in fluctuation in steady- state level and therefore better control 
 of disease condition. 
• Increased safety margin of high potency drug due to better control of 
plasma levels. 
• Maximum utilization of drug enabling reduction in total amount of dose 
administered. 
• Reduction in health care cost through improved therapy, shorter 
treatment period. 
• Less frequency of dosing and reduction in personnel time to dispense, 
 administer monitor patients. 
• Better control of drug absorption can be obtained, since the high blood 
level peak that may be observed after administration of a dose of high 
availability drug can be reduced. 
Disadvantages of sustained release drug delivery system 
• Decreased systemic availability in comparison to immediate release 
conventional dosage form. This may be due to 
➢ Incomplete release 
➢ Increased first-pass metabolism, increased instability 
➢ Site specific absorption, pH dependent solubility, etc. 
• Poor in vitro-in vivo correlation.   
• Possibility of dose dumping. 
• Retrieval of drug is difficult in case of toxicity, poisoning, or 
hypersensitivity reactions. 
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• Higher cost of formulation. 
• The physician has less flexibility in adjusting dosage regimens. This is 
fixed by the dosage form design. 
Rationale for sustained release: 
• Drugs which are often administered repeatedly at specified time interval to 
maintain therapeutic level in blood or blood tissues. 
• Uniform drug response achieved by using different combination of doses 
and dosage interval. 
• However, the dosage regimen of an orally administered drug may be 
considered to be optimal when the therapeutic effect is maintained for the 
desired duration of the treatment at the lowest frequency of administration. 
• Frequent administration of dose produces side effect. 
1.3  PHYSICOCHEMICAL FACTORS INFLUENCING ORAL  
  SUSTAINED RELEASE DOSAGE FORM DESIGNING 
 The performance of a drug in its release pattern from the dosage form as 
well as in the body proper is a function of its properties. Most of the time this 
properties are restrictive rather than prohibitive, making sustained/convenient to 
describe the physiochemical properties of the drug.6 
Dose size 
 For orally administered systems, there is and upper limit to the bulk size of 
the dose to be administered.  In general, a single dose of 0.5 – 1 g is considered 
maximal for a convenient dosage form.  This also holds for sustained release 
dosage forms.  Those compounds that require a large dosing size can sometimes 
be given in multiple amounts or formulated in to liquid systems.  Another 
consideration is the margin of safety involved in administration of large amount of 
a drug with a narrow therapeutic range. 
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Aqueous solubility 
 Since drugs must be in solution before they can be absorbed.  Compounds 
with very low aqueous solubility usually suffer oral bioavailability problems 
because of limited gastrointestinal transit time of the undisclosed drug particles 
and limited solubility at the absorption site.  Unfortunately, for many compounds, 
the site of maximum absorption will also be the area in with the drug is least 
soluble. The choice of mechanism for oral sustained/controlled release system is 
limited by aqueous solubility of the drug. Diffusion, systems will be poor choices 
for slightly soluble drugs since the driving force for diffusion, the incorporated in 
matrix systems. In selecting polymer coatings for sustained/controlled system, the 
dissolution rate of a drug must be considered.  Some antibiotics and high 
molecular weight drugs may have reasonable well to excellent aqueous solubility, 
but very slow dissolution rates.  On the positive side, the slow dissolution rate of 
such compounds can be utilized to achieve sustained/controlled drug release by 
incorporation in a matrix system. 
 
Partition coefficient and molecular size 
 Partition coefficient and molecular size influence not only the permeation 
of a   drug across the biological membranes, but also diffusion across or through a 
rate-controlling membrane or matrix.  Drugs with extremely high partition 
coefficient (i.e., very oil-soluble) readily penetrate the membranes but unable to 
proceed further, while drugs with excessive aqueous solubility, i.e., low oil/water 
partition coefficients cannot penetrates the membranes.  A balance in the partition 
coefficient is needed to give an optimum flux for permeation through the 
biological rate controlling members. 
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Drug stability 
 Drugs that are unstable in the stomach can be placed in a slowly soluble 
form or have their release delayed until they reach the small intestine.  To achieve 
better bioavailability and controlled release of drugs that are unstable in the small 
intestine, a different route of administration should be chosen. Controlled release 
of nitro-glycerine is a good example. On the positive side, the presence of 
metabolizing enzymes at the site of administration or along the pathway to the 
target area can sometimes be utilized in controlled drug delivery. 
1.3  BIOLOGICAL FACTORS INFLUENCING ORAL   
   SUSTAINED RELEASE DOSAGE FORM DESIGN 
 The design of a sustained/controlled release product should be based on a 
comprehensive picture of drug disposition.  This would entail a complete 
examination of the ADME characteristics of a drug following multiple dosing.  
Every pharmacokinetic property and biological response parameter has a useful 
range for the design of sustained/controlled release products.12 
Biological half-life 
 The usual goal of an oral sustained release product is to maintain 
therapeutic blood levels over an extended period.  To achieve this, drug must enter 
the circulation at approximately the same rate at which it is eliminated.  The 
elimination rate is quantitatively described by the half-life(t1/2).  Each drug has its 
own characteristic elimination rate, which is the sum of all elimination process, 
including metabolism, urinary excretion, and all other processes that permanently 
remove drug from the blood stream. 
 Therapeutic compounds with short half-lives are excellent for sustained 
release preparations, since this can reduce dosing frequency.  However, this is 
limited, in that drugs with very short half-lives may require excessively large 
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amount of drug in each dosage unit to maintain sustained effect; forcing the 
dosage form itself to become limiting large.  Compounds with long half-lives 
more than 8 hours are also generally not used in sustained forms, since their effect 
is already sustained. 
Absorption 
 To maintain constant blood or tissue level of drug.  It must be uniformly 
released from the controlled release system and then uniformly absorbed.  
Usually, the rate-limiting step in drug delivery from a controlled release product is 
release from the dosage form rather than absorption.  The drugs absorption by 
specialized transport processes and drugs at special sites of the GI tract are also 
poor for controlled release products.  To formulate drugs at the lower limit of 
absorption rate constants in to controlled or sustained release systems, the desired 
rate constants of release systems, the desired rate constants of release from the 
dosage form would have to be even lower, resulting in decrease bioavailability.  
As the GI transit time is finite, a suitable controlled release system, giving a high 
fraction of dose absorbed, can be difficult to design.  In addition, the rate constant 
of release based on absorption consideration may be very different from that based 
on biological half-life considerations so that a compromise is achieved generating 
less than ideal release rates.  In essence, oral drugs which are slowly absorbed are 
poor for sustained dosage forms primarily because drug availability is limiting by 
GI transit time. 
Distribution 
 The distribution of drugs into tissues can be an important factor in the 
overall drug elimination kinetics since it not only lowers the concentration of 
circulating drug but it also can be rate limiting in its equilibration with blood and 
extra cellular fluid.  In the bound portion of a drug can be considered inactive and 
unable to cross membranes. 
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 At high binding one sees prolonged drug action.  The apparent volume of 
including binding, within the body.  Conceptually, this pharmacokinetic parameter 
can be viewed as a proportionality constant relating plasma or serum 
concentration of drug to total amount of drug in the body.  Consequently, the 
apparent volume of distribution assumes different values depending on the time 
course of drug disposition. The apparent volume of distribution influences the 
concentration and amount of drug either circulating in the blood or in target 
tissues.  It can also influence the elimination kinetics of a drug. 
 The total apparent volume of distribution for a drug at steady state can be 
calculated by 
                            VdSs=[(K12+K21)/K21]Vp 
Where, 
VdSs is apparent volume of distribution at steady state. 
K12 is the constant for distribution of drug form the central to peripheral 
compartment. 
K12 is that from the peripheral to control compartment. 
Vp is the volume of the central compartment. 
Metabolism 
 Metabolism of a drug can either inactivate an active drug or convert an 
inactive drug to an active drug to an active metabolite.  Metabolic alteration of a 
drug can occur in a variety of tissues, some of which are richer in enzymes than 
others. For example, the organ most responsible for metabolism is the liver and 
thus the greatest metabolic conversion occurs after a drug has been absorbed in to 
the general circulation.  Metabolism of a drug will be reflected in the elimination 
constant of a drug or by the appearance of metabolite. There are two areas concern 
relative to metabolism that significantly restrict sustained release product design.   
                              J= (1/A)dm/dt 
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 If the concentration gradient is liner and the thickness of the diffusion 
layer is h, 
                             dc/dx=(Cb-Cs)/h 
 where Cs is the concentration at the solid surface and Cb is the 
concentration in the bulk solution. By combining the above equation, the flow rate 
of material is given by 
  Dm/dt=-(DA/h)(Cb-cs)= kA(Ca-cb) 
 Where k is the intrinsic dissolution rate constant. 
 The above equation predicts constant dissolution rate if the surface area, 
diffusion coefficient, diffusion layer thickness, and concentration differences are 
kept constant. 
Most of the products fall into two categories 
• Encapsulation dissolution control 
• Matrix dissolution control 
Encapsulation dissolution control 
  These methods generally involve coating individual particles or granules 
of drug with a slowly dissolving material. The coated particles can be compressed 
directly into tablets as in space tabs or placed in capsules as in the spanule 
products. 
Matrix dissolution control 
 The reduced drug solubility plus larger particle size can be used to modify 
available rates. There is an upper restriction on the size of  particles one can 
employ for the oralzoute while the low solubility approach will produce a 
changing dissolution are as the area for dissolution decrease. An alternate 
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approach is to compress the drug with a slowly dissolving carrier of some sort in 
to a tablet form. Here, the rate of drug availability is controlled by the rate of 
penetration of the dissolution fluid in to the matrix. This, in turn, can be controlled 
by porosity of the tablet matrix, the presence of hydrophobic additives, and the 
wettability of the tablet and particle surface. The porosity of the tablet, i.e., surface 
area available, can be altered in a compressed tablet by compression force, 
adhesion between adjacent particles as well as size and shape of the particles. In 
addition, hydroscopic fillers can be added to decrease the effective porosity be 
limiting the number of pores that can be penetrated by the eluting fluid. 
 A major disadvantage of matrix devices is that drug release rate 
continuously decreases with time. This is a consequence of increase diffusional 
distance and decreased surface area at the penetrating solvent front. Consequently 
to achieve zero order release from matrix devices is will be necessary to select a 
geometry that compensates the increase in diffusional distance with a 
corresponding increase in surface area for dissolution. In principal these systems 
can be used in oral controlled delivery where absorption at the specific site in the 
intestine is desired.10 
1.5.2  Diffusion controlled release 
 There are basically two types of diffusion controlled systems which have 
been developed over the past two decades: reservoir devices and matrix device. 
Reservoir devices 
 In this system, a water insoluble polymeric material encloses a core of 
drug .Drug will partition in to the membrane and exchange with the fluid 
surrounding the particle or tablet. Additional drug will enter the membrane. 
Diffuse to the periphery, and exchange with surrounding media.11 
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 The flux of drug, J (in amount/area-time),across a membrane in the 
direction of decreasing concentration is given by ficks first law: 
                                         J=-D dC/dx 
 Where D is the diffusion coefficient in area/time and dc/dx is the change 
of concentration C with a distance X. Assuming steady state, above equation can 
be integrated to give: 
                                          J=-D C/1 
 In Terms of the amount of drug released, the release rate Dm/dt is given by 
                    dM/dt=ADK.AC/1 
Where, 
 A is the area, 
 D is the diffusion coefficient, 
 K is the partition coefficient of drug between the membrane and drug core, 
 I is the diffusional path length (thickness of coat in the ideal case), and 
 C is the concentration difference across the membrane. 
 As important parameter in above equation is the partition coefficient which 
is defined as the concentration of drug in membrane over all concentration drug in 
the core. If the partition coefficient is high. The core will depleted of drug in a 
short time so that zero order release will be observed only over short segment of 
the time course of drug release.10  
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Matrix devices 
 In this system, a solid drug is dispersed in an insoluble matrix. The rate of 
drug release is dependent on the rate of drug diffusion but not on the rate of solid 
dissolution. The appropriate equation describing drug release from this system has 
been derived by T.Higuchi. 
                         Q= (D€/T(2A-€C,)C,t)1/2 
Where, 
 Q=weight in grams of drug release per unit surface area 
 D=diffusion coefficient of drug in the release medium 
 €=porosity of the matrix 
 T=tortuosity of the matrix 
 Cs=solubility of drug in the release medium 
 A=concentration of drug in the tablet, expressed as g/m. 
          For purposes of date treatment the above equation is usually reduced to; 
                             Q=Kt1/2 
 Therefore a plot of amount of drug released versus the square root of time 
should be linear if drug release from the matrix is diffusion controlled. 
1.5.3. Diffusion and dissolution controlled systems: 
 The main feature is that the drug core is enclosed with a partially soluble 
membrane. Dissolution of part of the membrane allows for diffusion of the 
continued drug through pores is the polymer coat. The release profile of drug from 
this type of product can be described by the following equation: 
 Release rate = AD(C1-C2)/1 
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 Where A, D and I are the surface area, diffusion coefficient of drug 
through pore, and diffusion path length, respectively.  C1 as the concentration of 
drug in the core and C2 is that in the dissolution medium.  The fraction of soluble 
polymer in the coat will be dominant factor controlling drug release. 
1.5.4  Ion-exchange resins: 
 It is an attractive method for sustained drug delivery because, in theory, 
drug release characteristics rely only on the ionic environment of the resin 
containing the drug and should therefore be less susceptible to environmental 
conditions.  Such as enzyme content and pH, at the site of absorption.  Resins are 
water-insoluble materials containing anionic or cationic groups in repeating 
positions on the resin chain.  When a high concentration of an appropriately 
charged ion is in contact with the ion-exchange group, the drug molecule is 
exchanged and diffuses out of the resin to the bulk solution according to the 
following scheme. 
                         Resin [M(CH3
+Z Resin [N(CG3)] 
+Z+X- 
Or 
              Resin (SO3)A
++B+ resin (SO3) B
++A+ 
              Where X- and A+ are drug ions 
 Before the eluted Ion an diffuse out, the eluting ions must diffuse into the 
resin matrix and establish and establish equilibrium with the ionic resin group.  As 
with all diffusion process, the area of diffusion and diffusional path length are 
important to the rate of diffusion, In addition, the amount of solvent in the matrix 
of the resin, as well as the structural rigidity of the resin, i.e. cross-linking, also 
influences the drug diffusion rate.  For this reason, the porosity of the resin and 
the size of the bead of particle must be carefully controlled during the formulation 
process.11 
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1.5.5 RELEASE MECHANISM OF MATRIX SYSTEM: 
 Higuchi provided the theoretical basis for defining drug release from inert 
matrices.  The equation describing drug release from the plannar surface – of an 
insoluble matrix is 
 DMt/dt= A [square root of(2DcsCo)]/A [square root of (t)] 
 Where, d Mt/dt = the rate of drug release form surface of the system, 
 A = surface area of system 
 D = drug diffusion coefficient through polymer, 
 Cs = drug solubility in polymer, 
 Co = total drug concentration in the matrix and it is the time. 
           Q = ([D€ Cg/T) [2A-C-Cs] t]1/2………………………..(1) 
   Where, 
 Q is the amount of drug release per unit surface after time t. 
 € is the porosity of the matrix 
 D is the diffusion co-efficient 
 T is the tortuosity of the matrix 
 Cs is the solubility of the drug in the elution medium 
 A is the initial loading dose of drug in the matrix 
 Drug release is triggered by penetration of eluting media into the matrix 
dissolving the drug, thereby creating channels through which diffusion takes 
place. A 
 High tortuosity means that the effective average diffusion path is large.  
The porosity items takes in to account the space available for drug dissolution; an 
Introduction 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique 16 
increased porosity results in increased drug release.  Both porosity and tortuosity 
are functions of the amount of dispersed drug, the physio chemical properties of 
the matrix, and the dispersion characteristics of the drug in the matrix. 
 If the drug is freely soluble in the elution medium that is Cs>>A, such that 
the dissolution rate is rapid, then equation(2), which describes the release of drug 
from a solution entrapped in an insoluble matrix applies: 
 Q = 2A (Dt/IIT)1/2…………………………………….(2) 
 Release rate is directly proportional to the amount of dispersed drug A: it 
is proportional to A1/2 for insoluble drugs if 2A = Cs.  These expressions predict 
the plots of Q Vs. t1/2 be linear.  Release of water soluble drugs, however should 
be unaffected by the amount of liquid pH value, enzymes content and other 
physical properties of digestive fluids, unless the drug is in a salt from that 
precipitates within the matrix pores on dissolution when penetrated by acidic or 
basic media.  Release kinetics. 
 To study the mechanism of drug release from matrix tablets, the release 
data were fitted to the following equation: Zero-order equation = Qo – kot (1) 
Where Q is the amount of drug release at time t, and ko is the release rate; 
 First – order equation ;  In Q = In Qo – k1t(2) 
 Where K1 is the release rate constant: 
 Higuchi’ equation: Q = K2t ½ (3) 
 Where Q is the amount of drug release at time t, and k2 is the diffusion rate 
constant.12 
SOLID DISPERSION      
          The term solid dispersion refers to a group of solid products consisting of 
at least two components, generally a hydrophilic matrix and a hydrophobic drug. 
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The matrix can be either crystalline or amorphous. The drug can be dispersed 
molecularly, in amorphous particles or in crystalline particles. 
         Oral availability of drug depends on its solubility and/or dissolution rate, 
therefore major problems associated with these drugs was its very solubility in 
biological fluids, which results into poor bioavailability after oral administration. 
Many methods are available to improve dissolution rate, solubility characteristics, 
including salt formation, micronization and addition of solvent or surface active 
agents. The term solid dispersion refers to a group of solid products consisting of 
at least two components, generally a hydrophilic matrix and a hydrophobic drug. 
The matrix can be either crystalline or amorphous. The drug can be dispersed 
molecularly, in amorphous particles or in crystalline particles. 
 Solid dispersion is one of these methods, which was most widely and 
successfully applied to improve the solubility, dissolution rates and consequently 
the bioavailability of poorly soluble drugs. The concept of solid dispersions (SDS) 
was introduced in 1961 by Sekiguchi and Obi, in which the drug is dispersed in 
inert water-soluble carrier at solid state. Several water soluble carriers such as 
hydroxyl propyl methyl cellulose, ethyl cellulose, beta cyclodextrin, urea, lactose, 
citric acid, poly vinyl pyrrolidone(PVP) and poly ethylene glycols such as carriers 
for Solid dispersion.15 
Advantages of solid dispersion  
➢ Particles with reduced particle size 
➢ Particles with improved wettability 
➢ Particles with higher porosity 
➢ Drugs in amorphous state. 
Disadvantages of solid dispersion 
 Though they increase the bio-availability of the drugs by increasing the 
solubility, their commercial use has been limited primarily because of 
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➢  Formulation development 
➢ Solid state structure 
➢ Mechanisms for dissolution enhancement are poorly understood in 
 majority of cases. 
➢ Manufacturing difficulties 
➢ Stability problems 
➢ Scale up. 
CARRIERS USED AND THEIR CHARACTERISTICS: 
 The most commonly used hydrophilic carriers for solid dispersion includes 
➢ Polymers like PVP, PEG, HPMC etc., 
➢ Lipids such as polyglycolized glycerides 
➢ Surface active carriers 
➢ Cyclodextrins. 
CHARACTERISTICS: 
➢ Hydrophilicity 
➢ Physically and chemically inert 
➢ Good solubility for drugs 
➢ Compatibility with other ingredients of formulations 
➢ Non toxicity. 
FACTORS GOVERNING DRUG RELEASE FROM SOLID 
DISPERSION 
1. Natural carrier 
       More hydrophilic nature of carriers enhances the faster release of drugs 
from solid dispersion. A poor water soluble or insoluble carriers may leads to 
slower release of drug. 
 
Introduction 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique 19 
2. pH dependent 
             As active drug incorporated into pH dependent polymers and was present 
dispersion state, the release of the drug from solid dispersion depends on the 
dissolution rate of the polymers which is mainly influenced by pH of the 
dissolution medium. 
3. Effect of other excipients on drug release 
             The dissolution rate of the drug is increased when excipient like 
solubilising excipients are incorporated into the solid dispersion. 
• When hydrophilic and lipophilic excipients where combined and 
incorporated, a remarkable enhancement of dissolution rate was observed. 
• Incorporating self -micro emulsifying excipient also enhanced dissolution 
 by forming dispersible particles with in the aqueous medium. 
• Solid dispersion with no pharmaceutical excipient incorporated, enhanced 
the dissolution rate to certain extend only, It is only two fold compare to 
pure drug.16 
PREPARATION OF SOLID DISPERSIONS: 
Various preparation methods for solid dispersion are; 
• Fusion method  
• Solvent method 
• Melting solvent method (melt evaporation) 
• Melt extrusion method 
• Lyophilisation Technique 
• Melt Agglomeration Process 
• The use of surfactant 
• Super Critical Fluid (SCF) Technology 
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• Co-precipitation method 
• Gel-entrapment method 
• Kneading method 
CHARACTERISATION OF SOLID DISPERSION 
A. Detection of crystallinity in solid dispersions. 
B. Detection of molecular structure in amorphous solid dispersions. 
  Currently, the following technique are available to detect (the degree of ) 
crystallinity 
1. Powder X-ray diffraction 
2. Infrared spectroscopy (IR) 
3. Water vapour sorption 
4. Isothermal micro calorimetry 
5. Dissolution calorimetry 
6. Macroscopic techniques. 
Alternative strategies: 
A. Spraying on sugar beads using a fluidized bed coating system 
B. Direct capsule filling 
C. Electrostatic spinning method 
D. Surface-active carriers.17 
Enhancement of drug release from solid dispersions: 
 The increase in dissolution rate achieved by solid dispersion is by a 
combination of following effects, 
• Reduction of particle size to such an extend can’t be achieved by other 
 conventional methods. 
• By increasing the wettability of drugs as it is hydrophilic in nature. 
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• Reduced aggregation  and agglomeration. 
• By increasing its solubility in water due to hydrophilic nature of carrier. 
• However, the main mechanism controlling the release of drug from the 
solid dispersions are not fully understood an proposed theories are 
depended on understanding of dissolution behavior of both the 
components of the dispersion. 
• Recently, a method of measurement of viscosity of dissolution medium as 
the polymer dissolves from the solid dispersion as used to know the 
amount of drug release. This is Micro viscometry techniques(MVT).20 
 
Figure 2: Schematic representation of the bioavailability enhancement of poorly 
water soluble drug   by solid dispersion technique. 
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Methods to increase solubility: 
 By using the following methods solubility can be increased, 
A. Kneading method 
B. Precipitation method 
C. Solid dispersion/ Co evaporated dispersion 
D. Spray drying 
E. Freeze drying 
F. Melting 
G. Neutralization method 
H. Grinding     
APPLICATION OF SOLID DISPERSION 
• To increase the solubility, dissolution rate, absorption and bioavailability. 
• Improved the stability. 
• To reduce side effect of certain drugs. 
• Masking of unpleasant taste and smell of drugs 
• Improvement of drug release from ointment, tablets, creams.13 
ARTHRITIS: 
 “Arthritis” literally means “inflamed joints”. Arthritis primarily affects the 
joints; it also attacks muscles and connective tissues of the surrounding organs. 
Arthritic disease stems from injuries, defects in the immune system, wear a tear on 
the joints, infections or genetic predisposition.21 
A. Osteoarthritis: 
 A degenerative joint disease and the most common of arthritis and joint 
disorders, is the gradual deterioration of cartilage, usually in the larger, weight 
bearing joints such as the hips, knees, and spine. This wear and tear is normal 
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process predominantly found in people of age 55 and older. It occurs more often 
in men. The joints are not always inflamed; the articular cartilage may begin to 
flake and crack, due to over use or injury. In severe cases the underlying bone 
becomes thickened and distorted. Scar tissue may then replace damaged cartilage. 
If movement becomes painful and restricted, lessened use of the associated 
muscles will lead to their atrophy. 
 
B. Rheumatoid arthritis: 
 Rheumatoid arthritis is traditionally considered a chronic, inflammatory 
autoimmune disorder that causes the immune system to attack the joints. It is a 
disabling and painful inflammatory condition, which can lead to substantial loss of 
mobility due to pain and joint destruction. Rheumatoid arthritis is a systemic 
disease, often affecting extra articular tissues throughout the body including the 
skin, blood vessels, heart, lungs, and muscles. 
 The joint lining, called the synovium, becomes inflamed in case of 
rheumatoid arthritis, leading to pain, stiffness, warmth, redness and swelling. 
These inflamed cells release an enzyme that may even digest cartilage and bone. 
  A number of different pathological mechanisms are involved in rheumatoid 
arthritis. Lymphocytes have an important role and many inflammatory cells in the 
synovial sublining layer are lymphocytes, especially T cells. 
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Figure 3: The pathophysiology of Rheumatoid Arthritis 
Treatment: 
 Pharmacological treatment of rheumatoid arthritis can be divided into 
• Disease modifying anti-rheumatic drugs. 
• Anti-inflammatory agents and analgesics. 
• DMARDS have been found to produce durable remissions and delay or 
halt disease progression. In particular they prevent bone and joint damage 
from occurring secondary to the uncontrolled inflammation. 
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Disease modifying anti-rheumatic drugs (DMARDS): 
 DMARDS can be further subdivided into Xenobiotic agents and biological 
agents. Xenobiotic agents are those DMARDS that do not occur naturally in the 
body, as opposed to biological.22 
Xenobiotics include: 
 Azathioprine, Cyclosporine, D-penicillamine, gold salts, Leflunomide, 
Minocycline, Hydroxychloroquine, Methotrexate, and Sulfsalazine. 
Biological agents: 
 Tumor necrosis factor (tnf α) blockers - Etanercept (Enbrel), Infliximab 
(Remicade), 
     Interleukin-1 blockers                         -   Anakinra 
     Anti-B cell (CD20) antibody               - Rituximab   
Anti-inflammatory agents and analgesics: 
 The treatment of arthritic conditions relies on medicines tht fight joint 
swelling, stiffness and pain. Circadian rhythm affects the arthritic medication. 
NSAIDS reduce the swelling, stiffness and pain of arthritis. Taking the medicines 
at the wrong time of day compromises their effectiveness and increases the risk of 
side effects such as indigestion, stomach ulcers, headache, anxiety and dizziness. 
Chronotherapy provides ways of increasing the effectiveness and safety of 
arthritic medications. 
Anti-inflammatory agents include, 
A. Glucocorticoids: 
 Non steroidal anti-inflammatory drugs also act as analgesics. 
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B. Non steroidal anti-inflammatory drugs: 
            NSAIDS are drugs with analgesic, antipyretic and anti-inflammatory 
effects  that reduce pain, fever and inflammation. The term “non steroidal” is used 
to distinguish these drugs from steroids, which (among a broad range of other 
effects) have a similar eiconsid depressing, anti-inflammatory action.23 
Mechanism of action: 
  Most NSAIDS act as non selective inhibitors of the enzyme 
cyclooxygenase, inhibiting both the cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2) isoenzymes. 
 Cyclooxygenase catalyzes the formation of prostaglandins and 
thromboxane from arachidonic acid (Derived from the celluar phospholipid 
bilayer by phospholipase A2). 
 
Figure 4: Mechanism of action of NSAIDS 
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Classification of NSAIDS: 
A.  Chemical classification: 
                               Table 1: The structural Classification of NSAIDS 
S.No. Chemical Class Examples 
1. Salicylates Aspirin 
2. Quinolines Cinchophen 
3. Pyrazoles Phenyl butazone 
4. Indolines Indomethacin, Eltenac, Tepoxalin 
5. Propionic acid Ibuprofen, ketoprofen 
6. Anthranilic acids 
Flunixin, Meclofenamic acid, 
Tolfenamic acid 
7. Oxicams Piroxicam, Tenoxicam, Meloxicam 
8. Sulphonamide Derivatives Nimesulide 
9. Coxibs 
Celecoxib, Rofecoxib,Valdecoxib, 
Parecoxib 
10. Aryl propionic acid Naproxen 
 
B. Classification based on COX selectivity: 
1. Non COX selective NSAIDS: 
 Aspirin, Indomethacin, Diclofenac  
2. Preferential COX-2 inhibitors: 
 Nimesulide, Meloxicam, Nabumetone, Ibuprofen 
3. Highly selective COX-2 inhibitors: 
 1st generation  : Celecoxib, Rofecoxib 
 2nd generation : Valdecoxib, Parecoxib, Etoricoxib.23 
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Need for developing the Ibuprofen as Sustained release tablet: 
        Several reasons are there for attractiveness of sustained release drug delivery 
system, it provides increased bioavailability, reduction in the frequency of 
administration, reduces the fluctuation of plasma concentration and side effects 
and possibly improves the specific distribution of the drug. From this the 
sustained release formulation of Ibuprofen by solid dispersion technique, 
promising way to improve the patient compliance by reducing dosing interval and 
minimizing adverse effect. 
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AIM AND OBJECTIVE 
AIM: 
    The aim of the present study is to formulate and evaluate the sustained 
release tablets of Ibuprofen by solid dispersion technique. 
OBJECTIVE: 
❖ To prepare the solid dispersion of Ibuprofen.     
❖ Drug excipients interaction by FTIR studies. 
❖ Formulation of sustained release tablets of Ibuprofen solid dispersion with 
concentration of rate controlling polymers like HPMCK4MCR, 
HPMCK100MCR. 
❖ The formulated tablets are evaluated for weight variation, hardness, 
friability, drug content, in vitro dissolution study, study of release kinetics. 
❖ To perform stability studies as per ICH guidelines.   
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PLAN OF WORK 
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LITERATURE REVIEW 
 Kimia Fazaeli Kahkeshan et.al., studied solid dispersion technique: 
methods and polymers to increase the solubility of poorly soluble drugs. Solid 
dispersions in water-soluble carriers have engrossed considerable interest as a 
means of improving the dissolution rate and bioavailability of hydrophobic drugs. 
Although solid dispersions have tremendous potential for improving drug 
solubility and only a few marketed products using this approach. A solid 
dispersion generally composed of two components the drug and the polymer 
matrix. Numerous methods are existing to prepare the solid dispersions such as 
melting method, spray drying method, co-grinding method, lyophilisation 
technique, hot melt extrusion, melt agglomeration, super critical fluid technology 
etc. A variety of hydrophilic carriers have been investigated for enhancement of 
dissolution characteristics and bioavailability of poorly aqueous soluble drugs.18 
 Meka Anand Kumar et.al., developed and evaluation of the solid 
dispersion formulated ibuprofen tablets using cyclodextrins as a carrier. In the 
present investigation, an attempt was made to increase the therapeutic 
effectiveness of ibuprofen, by increasing the solubility, via solid dispersion using 
beta cyclodextrin (β-CD) and 2- hydroxyl propyl beta cyclodextrins (2-HPβ-CD) 
as carrier. Eight solid dispersion formulations of ibuprofen were prepared by using 
different drug: polymer ratios viz. 1:0.5, 1:1, 1:2, and 1:3 for (2-HPβ-CD) and β 
cyclodextrin by co-evaporation method and optimized solid dispersions were 
evaluated for drug content, In-vitro release studies, FTIR, differential scanning 
calorimeter (DSC). No interaction between ingredients was confirmed by FTIR, 
DSC. The formulation with better drug release was selected and compressed into 
tablet with weight equivalent to ibuprofen of 400mg.the compressed tablet were 
evaluated for its hardness, disintegration, weight variation, friability and drug 
content, compared with marketed tablets and finally loaded for stability at 
40ºC/75%RH and the results found to satisfactory.29 
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 Gul Majid Khan et.al., prepared and evaluation of solid dispersions of 
ibuprofen using glucosamine HCL as a carrier. Ibuprofen is sparingly water-
soluble drug and has low bioavailability, so to enhance its solubility and improve 
bioavailability solid dispersions with different drug  to carrier ratios (1:1, 1:2, and 
1:3) were prepared, as solid dispersion is the most effective method for enhancing 
the solubility and improving the bioavailability of poorly sparingly water-soluble 
drug. In this study glucosamine HCL was used as a potential hydrophilic carrier to 
improve the solubility, dissolution rate and bioavailability of poorly water-soluble 
drug, Ibuprofen from physical mixtures and solid dispersions. Solid dispersions 
with different drug to carrier ratios were prepared, using solvent evaporation 
method. Physical mixtures of ibuprofen and Glucosamine HCL were also 
prepared for comparison.30  
 Rupali S.Joshi et.al., developed and validation of UV spectrophotometric 
method’s for simultaneous estimation of Ibuprofen. The concentration range 
between 5-30µg/ml and absorbance maximums at 222.4nm respectively. Methods 
are validated according to ICH guidelines and can be adopted for the routine 
analysis of ibuprofen in pure and tablet dosage form.31 
 Hapse S.A et al., studied simple, sensitive and specific spectrophotometric 
method were developed and validated for quantification of ibuprofen by 
difference spectroscopy. Ibuprofen exhibits a substantial difference in absorbance 
in the two solvents that is in 0.1 N HCL and 0.1 N NaoH at 222nm. Beer’s law 
was obeyed in the concentration range of 5 to 40 µg/ml for ibuprofen. Results of 
tablet analysis showed standard deviation in the range of 0.3694 to 1.851 for 
ibuprofen which indicate repeatability of the method. The results indicated 
excellent recoveries ranging from 101.13 to 101.23% for ibuprofen with a mean of 
101 %. Recoveries obtained do not differ significantly from 100% showed that 
there was no interference from the common excipients used in the tablet 
formulation indicating accuracy and reliability of the method.32 
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 Yousry M. Issa et al., studied simple, rapid and accurate new method is 
described for the simultaneous determination of ibuprofen and paracetamol in two 
components mixture and cetofen tablets. The method depends on the derivatives 
of the ratio spectra DD by measurement of the amplitude of DD at 225.6 nm and 
the amplitude of DD at 238.9 nm for IB and PA. Calibration graphs are linear in 
the range 2-32 (LOD 0.53) and2-24 (LOD 0.57) µg/ml IB and PA, respectively. 
The proposed method is successfully applied for simultaneous determining IB and 
PA in authentic mixtures and cetofen tablets.33 
 Hugo Almeida et al., Studied prolonged- release solid dispersions of 
ibuprofen. Ibuprofen (IB) is the one of the most important non-steroidal anti-
inflammatory drugs used in the treatment of inflammatory chronic diseases. This 
drug presents, in pure state, poor physical and mechanical characteristics and their 
use in solid dosage forms needs the addition of excipients which improve these 
properties. The selection of the best excipients and the suitable pharmaceutical 
dosage form to carry ibuprofen are very important for the industrial success of this 
drug. Solid dispersions of ibuprofen with stearic acid and hydrogenated castor oil 
showed better flow characteristics than pure ibuprofen and the respective physical 
mixtures. Gelatin capsules filled with solid dispersions were submitted to 
dissolution tests in order to study the influence of the prepared systems in the 
release profiles of ibuprofen. Prolonged-release of ibuprofen was achieved with 
the solid dispersions prepared with the different types of excipients.39 
 R.Margret chandira et al., formulated and evaluation the oral tablets 
Ibuprofen. The purpose of the study is to investigate the effect of roller 
compaction (RC) parameter (auger speed) on the properties of flakes, granules and 
tablets. This study is carried out in six formulation preparing by changing auger 
speed(6-7, 10-11, 14-15, 18-19, 23-24, 27-28 rpm) of roller compactor resulting in 
flakes of different hardness were prepared, and its impact on the flow 
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properties(bulk density, tapped density) of the granules and finally its effect on the 
properties of tablet such as hardness, thickness, friability. For this study ibuprofen 
is the model drug selected and the tablets formed by changing the auger speed is 
of ibuprofen. In this study the tablet’s in vitro drug release were also performed 
and compare with the marketed ibuprofen tablet.40 
 M.M.Gupta et al., studied enhancement of dissolution rate of ibuprofen 
by preparing solid dispersion using different methods. Ibuprofen is absorbed 
rapidly, bound avidly to protein, but it has low aqueous solubility so, it also 
lowers the dissolution profile of drug ibuprofen was increased by preparing solid 
dispersion with urea in ratio of (1:1),(1:3) and (1:5) by using melt dispersion 
method and solvent evaporation method. The rate of dissolution of ibuprofen was 
increased with the proportion of (1:5) when compared to other formulations.41 
 Abhik kar et al., enhancement of solubility and dissolution of ibuprofen 
by solid dispersion technique and formulation of sustained release tablets 
containing the optimised batch of solid dispersion. Solid dispersions of ibuprofen 
were prepared by using PEG 20000 and poloxamer 407 in different weight ratios 
by fusion and solvent evaporation method. Drug-carrier physical mixtures were 
also prepared. Solid dispersions were characterized by saturation solubility, drug 
content, in-vitro dissolution, FTIR and DSC analysis. Sustained release tablets 
containing the solid dispersion granules the optimized batch were prepared by 
direct compression method. The prepared formulations were evaluated for 
hardness, thickness, weight variation, friability, in-vitro dissolution studies and 
release kinetic modelling.47 
 Madhuri Newa et al., were prepared and evaluation of fast dissolving 
Ibuprofen Polyethylene Glycol 6000 solid dispersions. To improve its oral 
absorption, rapidly dissolving ibuprofen solid dispersions were prepared in a 
relatively easy, simple, quick, inexpensive, and reproducible manner, 
characterized by scanning electron microscopy(SEM), differential scanning 
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calorimetry(DSC), and Fourier transform infrared spectroscopy(FTIR). They were 
evaluated for solubility, in vitro drug release, and oral bioavailability of ibuprofen 
in rats. Quicker release of ibuprofen from SDS in rat intestine resulted in a 
significant increase in AUC and Cmax, and a significant decrease in Tmax over pure 
ibuprofen. Preparation of fast- dissolving ibuprofen SDS by low temperature 
melting method using PEG 6000 as a meltable1 hydrophilic polymer could be a 
promising approach to improve solubility, dissolution, and absorption rate of 
ibuprofen.48 
 Sundar et al., designed and evaluation of sustained release tablets 
containing Solid dispersion of Ziprasidone hydrochloride. Ziprasidone 
hydrochloride solid dispersions were prepared with PEG 6000 and β-cyclodextrin. 
The efficient dispersions was further directly compressed to sustained release 
tablets with matrix polymers like guar gum and HPMC K15 in the ratios of 1:0.5, 
1:1, 1:1.5. Pre compression and post compression parameters were carried out 
along with compatibility studies and in vitro drug release studies. The influence of 
polymers on the release rate and mechanism of drug release for Ziprasidone 
hydrochloride from matrix tablets were determined. The mechanism of release of 
drug from the formulations was observed to be  diffusion controlled exhibited by 
higher correlation with Higuchi kinetics. To confirm the exact mechanism of  drug 
release from these tablets, the data were fitted to Korsemeyer-peppas equation. 
Slope values >0.5 suggested that the release of Ziprasidone hydrochloride from 
the sustained release solid dispersion tablets revealing the fickian drug transport 
mechanism.49    
 Suja C Jayan et al., formulated and evaluation of ibuprofen tablets using 
Gum of Anacardium Occidentale as binding agent. Anacardiumgum derived from 
the edible seeds of Anacardiumoccidantale(family Anacardiaceae) was evaluated 
for its binding properties at a concentration of 5% w/w and 10%w/w in ibuprofen 
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tablets with official starch as a control. The hardness, disintegration time and 
dissolution rate increased with increase in concentration of Anacaediumgum. 
Tablets containing 10%w/w of Anacardiumgum had a binding capacity 
approximately twice that of starch with a dissolution rate of 58.5% after 30 min.50 
 Sachin K Gawai et al., studied In vivo-In vitro evaluation of solid 
dispersion containing Ibuprofen. Solid dispersion technique can be used to 
enhance the solubility, dissolution rate and absorption of several insoluble drugs. 
The different solid dispersion methods were studied using PEG 6000 as carrier. 
Tests of physical evaluation, drug content, loss drying and in vitro dissolution 
were carried out. In-vivo anti- inflammatory activity of 1:2 ratio formulation of 
fusion method shows highest dissolution and absorption rate than marketed 
preparation. The present study concluded with the importance of solid dispersion 
technique and their methods in enhancing the solubility of poorly water soluble 
drug.51 
 M.Sunitha Reddy et al., formulated and evaluation of ibuprofen sustained 
release matrix tablets using Manlikara Zapota Gum as a release retarding polymer. 
Properties of plant gum obtained from sapota fruit were studied. Physicochemical 
characterization of the gum was done by carrying out solubility test, loss in 
drying, total ash, pH determination, swelling characteristics and micromeritic 
properties. In-vitro drug release studies were carried out in pH buffer-7.2 for 12 
hours. Effect of gum in different concentrations on release kinetics evaluated. The 
total ash and acid insoluble value of Manlikara Zapota gum was found to be 2.28 
and 1.0 % w/w respectively. The swelling index is high in distilled water followed 
by phosphate buffer. Due to the short half-life (2-4hrs), an ibuprofen sustained 
release tablets were prepared by wet granulation method using Manlikara Zapota 
gum as a retarding polymer. The dissolution studies were performed using U.S.P 
apparatus type-2 using pH 7.2 phosphate buffers as dissolution medium. These 
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studies showed that formulation consisting of polymer was found to sustain the 
release of ibuprofen over a period of 12hrs. Manlikara Zapota gum as binder was 
of good mechanical strength and acceptable friability values. This implies that the 
gum can be used for intestinal drug delivery. Formulation was subjected to 
different kinetic models including zero order, first order, higuchi  model, and 
korsemeyer peppa’s model and the formulation was found to follow first order 
kinetic model. The final optimized formulation was subjected to accelerated 
stability for 3 months according to I.C.H guidelines.52 
 Mohammed Omar et al., formulated and in vitro evaluation of immediate 
release tablets of fenofibrate solid dispersions by different techniques. Fenofibrate 
BCS class II Anti hyperlipidaemia drug belongs to fibrate class was formulated as 
solid dispersions by using various hydrophilic carriers to enhance the solubility, 
dissolution rate and oral bioavailability. Solvent evaporation method, Fusion 
Method, and Melt solvent method are used to prepare solid dispersions of 
fenofibrate. To develop the solid oral dosage form (Tablets) with fenofibrate solid 
dispersions. To study the physical parameters of tablets of tablets prepared by 
direct compression, which includes hardness, friability, weight variation, and 
disintegration. To estimate the % drug content in the solid dispersions and the 
fabricated formulations. To evaluate the drug release from the tablets by in-vitro 
dissolution studies and to compare in vitro dissolution profile of fabricated 
formulation with marketed formulation.53 
 Bhawandeep Gill et al., studied glimepiride is poorly water soluble drug, 
so solubility is the main constraint for oral its bioavailability. An attempt has been 
made to increase the solubility of this model drug by formulating solid dispersion 
using polaxmer 188 as polymer and then formulating SDS tablets of the best 
formulation of SDS. Tablet formulations were prepared by direct compression 
technique using superdisintegrant croscarmellose sodium in different 
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concentrations. SD containing drug is to polymer ratio 1:4 gives best dissolution 
profile and dissolution efficacy and among tablet formulations, formulations 
containing 5% croscarmellose sodium gives best disintegration and dissolution 
profiles compared with other formulations. Results showed that polaxmer is a 
promising polymer for enhancing the solubility of GMP.55 
 M Gopal Rao et al., prepared and evaluation of Solid dispersions of 
Naproxen using carriers such as PVP, PEG 4000, PEG 6000, PEG 20000, 
methylcellulose and β-Cyclodextrin with a view to develop fast release 
formulations of Naproxen. Solid dispersions of naproxen were prepared by 
solvent evaporation method and the dispersions were evaluated for drug content 
uniformity, dissolution rate, moisture absorption, thin layer chromatography, 
Scanning electron microscopy, and X-ray diffraction analysis. A marketed 
increase in dissolution rate. All the solid dispersions except naproxen-PVP were 
found to be non-hygroscopic. Naproxen was found to be in an amorphous form in 
solid dispersions. Selected dispersions of Naproxen-β-Cyclodextrin and 
Naproxen-methylcellulose were formulated into capsules with usual additives and 
evaluated for drug release characteristics.57 
 M. Mohan Varma and P. Sathish Kumar formulated and evaluation of 
Gliclazide tablets containing PVP-K30 and Hydroxyl-β-cyclodextrin solid 
dispersion technique. Solid dispersions were prepared using PVP-K30 and 
Hydroxypropyl-β-cyclodextrin as the hydrophilic carriers. The solid dispersions 
were characterized by using DSC, XRD and   FT-IR. The formulated tablets were 
evaluated for the quality control parameters and dissolution rates. The optimized 
formulation showed a 3 fold faster drug release compared to the branded tablet. 
The XRD studies demonstrated the remarkable reduction in the crystallinity of the 
drug in the solid dispersion. The faster dissolution rate of the drug from the solid 
dispersion is attributed to the marked reduction in the crystallinity of the drug. The 
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DSC and FTIR studies demonstrated the absence of the drug-polymer 
interaction.66       
 Anusha Pagadala et al., studied formulation and evaluation of solid 
dispersion of solid dispersion of Glimepiride in to sustained release. Solid 
dispersions of glimepiride were prepared by using Urea and PEG 6000 as carrier 
in drug: carrier 1:1, 1:2, 1:3, 1:4 ratios by fusion method. From these all solid 
dispersions formulation SDUF3 containing Urea shows better dissolution 
compared to other solid dispersions. This optimized solid dispersion is formulated 
into sustained release tablets by direct compression method using hydroxyl propyl 
methyl cellulose and ethyl cellulose polymers.67 
 Syed Shariff Miyan et al., designed and development of fast dissolving 
tablets of Gliclazide by solid dispersions technique. The solubility of poorly 
soluble drug was enhanced by preparing solid dispersions of the drug with PEG 
6000 in various concentrations. The optimized solid dispersions (Drug: PEG 6000 
1:2 ratio) were further kneaded with suitable proportions of superdisintegrants 
such as; Crosscarmellose, Sodium starch glycolate and Crosspovidone. Fast 
dissolving tablets of Gliclazide was prepared by direct compression method. The 
pre-compressive parameters for the blends and post –compressive parameters for 
the prepared tablets were evaluated. Short term accelerated stability study was 
performed for optimized formulation and found no evidence of physical and 
chemical changes. FTIR study showed no evidence of drug-excipient interaction. 
The optimized formulation was found to be FDTG. It was concluded that fast 
dissolving tablets of Gliclazide can be prepared by solid dispersions of drug with 
PEG-6000 and combination of two superdisintegrants provide complete and better 
dissolution within in shorter period of time.68         
 
 S.L.Neha et al., formulated and sustained release solid dispersion of 
Metoclopramide HCL by solvent evaporation method. Several polymers like 
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combination of Eudragit RSPO, Eudragit RLPO and Guargum. Egg albumin as 
synthetic and natural polymers respectively were used. The In vivo studies were 
performed on Albino Wistar rats and various pharmacokinetic parameters were 
determined. The whole study was showed that the solid dispersion of 
Metocloproamide HCL sustained the release rate of drug for a prolong period of 
time at least 12hrs and shows to increase the bioavailability and simultaneously 
decrease the dosing interval as well as dosing amount. The formulation minimizes 
the blood level oscillations, dose related adverse effects and cost of ultimately 
improve the patient compliance and drug efficiency.69 
 
 Kenechukwu FC et al., studied characterization and In vivo evaluation of 
Ibuprofen-PEG 8000 solid dispersion were prepared by fusion method using 
varying combination ratios 1:1,1:2, 1:3, and 1:4. Characterization based on surface 
morphology, particle size, absolute drug content, FTIR and micromeritic 
properties were carried out on the SDS. The in vivo release of Ibuprofen from SDS 
was performed using rats. The FT-IR results indicate no strong chemical 
interaction of Ibuprofen and PEG 8000 in the SDS. Administration of the SDS  to 
rats resulted in much higher plasma concentration compared to the pure Ibuprofen 
and physical mixture (p<0.05), an indication of enhanced absorption rate of 
Ibuprofen in the SDS systems. This study has shown that Ibuprofen-PEG 8000 
SDS could offer a better and more effective approach of increasing the dissolution 
and absorption rate of the drug.70 
 Jani Rupal et al., prepared and evaluation of solid dispersions of 
Aceclofenac by solvent evaporation method. Dissolution of Aceclofenac increased 
with increase in the proportion of carriers (1:1, 1:5, and 1:9). Of both the carriers 
used, dissolution of the aceclofenac could be improved by solid dispersion and 
PEG 6000 based solid dispersions were more effective in the enhancing the 
dissolution.71 
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 Fayeza Tahseen A.B.Gangurde, formulated and development In-vitro 
evaluation of sustained release tablets of Carvedilol solid dispersion technique for 
improving solubility of Carvedilol using Poloxamer 407 and PVP K30. The 
Carvedilol tablets were prepared by direct compression method using HPMC K15 
as sustained release polymer in different concentrations. The prepared tablets were 
evaluated for various physiochemical parameters, n-vitro drug release study was 
carried out in simulated gastric fluid (0.1 N HCL) for the first 2hr and in 
phosphate buffer (pH 6.8) for the next 12hr following USP Type II paddle 
apparatus. Increase in HPMC concentrations resulted in a significant decrease in 
Carvedilol release. For instance, the tablets containing 20mg of HPMC K15 (F1 
and F4) shows 97% drug release upto 12hr when compared to 40mg and 60 mg of 
HPMC K15(F2,F3,F5, and F6) shows 98% drug release upto 14hr. The in-vitro 
data is fitted in to different kinetic models like Zero order, First order, Korsmeyer 
and Higuchi’s plot. The release of Carvediolol from the tablets containing solid 
dispersions of Poloxamer 407 and PVP K30 were shown early t50% 6.4hrs(F1 and 
F4) than it’s plane drug tablet formulation 9.5hrs (F7). From this study, it was 
clarified that solid dispersion technique was one of the promising sustained 
release system applying for poorly water soluble drugs.72 
  S Kumar and Satish Kumar Gupta, prepared and evaluation of solid 
disersions of Aceclofenac for the improvement of dissolution rate. The present 
work aims to prepare the solid dispersions of Aceclofenac by solvent wetting 
method by using potato starch as carrier in the ratios of 1:1 and 1:2 formulated 
solid dispersions were characterized for 1% practical yield, carr’s index, angle of 
repose, Hausner’s ratio, drug content and in vitro drug dissolution. In vitro release 
study has shown that there is an enhancement in the release rate of aceclofenac 
from all prepared batches in comparison to pure aceclofenac. Experimental results 
showed that formulation F2(1:2 ratio of drug: potato starch, prepared by solvent 
wetting method) showed more release in comparison to other batches.73 
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 Ganesh Chaulang et al., prepared and characterization of solid dispersion 
tablet of Furosemide with Crospovidone by using Kneading technique. 1:1(w/w) 
and 1:2 (w/w) solid dispersions were prepared by kneading method using solvent 
water and ethanol in 1:1 ratio. Dissolution studies, FTIR, DSC, and X-ray 
diffractometry were performed to identify the physicochemical interaction 
between drug and carrier, hence its effect on dissolution. Tablets containing solid 
dispersion exhibited better dissolution profile than commercial tablets. Thus, the 
solid dispersion technique can be successfully used for improvement of 
dissolution of Furosemide.74 
 S.K Swain et al., designed and evaluation of sustained release solid 
dispersion of Verapamil Hydrochloride. The results obtained showed that the rate 
of dissolution of Verapamil hydrochloride was considerably more sustained when 
formulated in solid dispersions with HPMC K4M and Eudragit RSPO as 
compared with pure drug and physical mixtures. FT-IR studies confirmed absence 
of any possible solid state drug and polymer interactions. In order to establish the 
mechanism and kinetics of drug release, the experimental data was fitted to 
different kinetic models like Zero order, First order, Higuchi model, Korsmeyer 
peppa’s model. From the above research it may be concluded that HPMCK4M 
acts as a better release retardant for the model drug.75 
 Samba Moorthy.U et al., formulated Sustained release of solid 
dispersions of Verapamil Hydrochloride using Ethyl cellulose and Eudragit-
RSPO. In present study the SD’s containing EC and Eudragit-RSPO at different 
drug-polymer ratios of 1:0.5, 1:1, 1:2, 1:3. 1:5,1:7, 1:7:0.75, 1:7:0.5, 1:7:0.75 as 
F1-VPH:EC, F2-VPH:EC, F3-VPH:EC, F4-VPH:RSPO,F5-VPH:RSPO, F6-
VPH:RSPO, F7-VPH:EC:RSPO, F8-VPH:EC:RSPO, F9-VPH:EC:RSPO 
respectively by solvent evaporation technique. The physical mixtures were 
prepared by physical mixing technique at the same ratio as solid dispersion. The 
physical mixtures were prepared by physical mixing technique at the same ratio as 
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solid dispersion. FTIR spectroscopy suggested that there was no major interaction 
between drug and polymers. The in-vitro release profile indicates that the release 
of VPH can be effectively controlled from a tablet containing S.D. The release 
data was analysed as per the peppa’s equation model indicating that the non-
fickian diffusion was the release mechanism.76 
 Kosika Sandeep formulated and evaluation of sustained release tablets 
from solid dispersion of Glipizide. The object of present study is to increase the 
solubility of Glipizide to enhance the bioavailability and to extent the release of 
drug. Natural polymers are xanthan gum, Guargum were used to sustain the 
release of the drug. Drug and excipient study show that no interaction between 
polymers and drugs. The tablets were evaluated for physical characteristics like 
hardness, weight variation, friability and thickness. It was found that drug release 
rate decreased with the amount of polymer increased in formulation. Use of 
xanthan gum as sustained material drug release is influenced. Magnesium sterate, 
talc were used to increase the flow property of the powder blend. Based on 
dissolution studies F5 showed sustained release of drug.77 
 Patil SA et al., formulated and evaluation of extended release solid 
dispersion of Metformin Hydrochloride using methocel K100M as the carrier by 
solvent evaporation and cogrinding method. The influence of drug polymer ratio 
on drug release was studied by dissolution tests. Characterization was performed 
by FTIR, UV, DSC and X-ray powder diffractometry. The optimized formulation 
was subjected to accelerated stability testing as per ICH guidelines. Release data 
were examined kinetically. SD with 1:4 and 1:5 ratio of drug to polymer obtained 
by solvent evaporation and cogrinding were selected as the best candicates 
suitable for prolonged-release oral dosage form of metformin.78 
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 K. Arun Prasad et al., prepared and evaluation of solid dispersion of 
Terbinafine Hydrochloride by using carriers polyethylene glycol 6000 (by melting 
method) and polyvinyl K 30(by solvent method) in the drug carrier ratio of 1:1, 
1:2 and 1:3. The prepared solid dispersions were characterized for their drug 
content, thermal studies, infrared spectral studies, differential scanning 
calorimetric studies, aqueous solubility studies and in-vitro release studies. From 
the results, it was clear that solid dispersion formulation showed improved 
dissolution rate than pure drug and physical mixture. The solid dispersion showing 
better release profile was chosen to formulate into a tablet dosage form weight 
600mg. The tablets compressed were evaluated for its physical parameters like 
thickness, hardness, weight variation, friability, drug content and disintegration 
tests. The dissolution profile of formulated tablet was compared with marketed 
product and the formulated tablet showed better release profile than the marketed 
product. 79 
 Rajeshree Panigrahi et al., studied Enhancement of solubility of 
Gliclazide by solid dispersion. The enhancement of oral bioavailability of poorly 
water-soluble drugs remains one of the most challenging aspects of drug 
development. Solid dispersions must be developed into convenient dosage forms, 
such as capsules and tablets, for their clinical use and successful 
commercialization. The initial solubility of pure drug Gliclazide was found to be 
8μg/ml. Solid dispersion of Gliclazide was prepared using Polyethylene glycol 
4000, Polyethylene glycol 6000, Mannitol, Low substituted Hydroxy propyl 
cellulose as carriers by kneading, Solvent evaporation and Solusorb method 
respectively. Different ratios 1:1, 1:3, 1:9 of drug: carrier is taken. The maximum 
enhancement of solubility was found in kneading method of ratio 1:1 using drug: 
low substituted hydroxyl propyl cellulose with 250%.80         
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DRUG PROFILE 
IBUPROFEN: 
    Ibuprofen is a medication in the non-steroidal anti-inflammatory drug 
(NSAID) class that is used for treating pain, fever, and anti-inflammation. This 
includes painful menstrual period, migraines, and rheumatoid arthritis. About 60% 
of people improve with any given NSAID, and it is recommended that if one does 
not work then another should be tried. It may also be used to close a patent dectus 
arterious in a premature baby. It can be used by mouth or intravenously. It 
typically begins working within an hour. 
     Common side effects include heartburn and a rash. Compared to other 
NSAID it may have fewer side effects such as gastrointestinal bleeding. It 
increases the risk of heart failure, kidney failure, and liver failure. At low doses, it 
does not appear to increase the risk of myocardia infraction; at higher doses it 
may. Ibuprofen can also result in worsened asthma.it is unclear if it is safe in early 
pregnancy, it appear to be harmful in later pregnancy and therefore is not 
recommended. Like other NSAIDSs, it works by inhibiting the production of 
prostaglandins by decreasing the activity of the enzyme cyclooxygenase. 
Ibuprofen might be weaker anti-inflammatory than other NSAIDs.23,25 
PROPRIETARY NAME: 
            Mortin, Advil, Mortin IB, IBU 
SYSTEMIC (IUPAC) NAME: 
           2-[4-(2-methylpropyl) phenyl] propionic acid 
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STRUCTURE 
 
Figure 5: Structure of Ibuprofen 
PROPERTIES: 
              Formula         :C13H18O2 
              Molar mass    : 206.29gm/mol 
              Chirality         :  Racemic mixture 
              Density           : 1.03g/cm 
                     Melting point  : 75 to 78ºC 
              Boiling point: 157ºC (315ºF)  
SOLUBILITY: 
              Freely soluble in acetone, in chloroform, in ethanol and in ether. 
Practically insoluble in water. It dissolves in dilute solutions of alkali hydroxides 
and carbonates.26 
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DECRIPTION: 
              A white or almost white, crystalline powder or colourless crystals; odour, 
slight.  
INDICATION: 
          Pain and inflammation in rheumatic disease and other musculoskeletal 
disorders including juvenile arthritis; mild to moderate pain including 
dysmenorrheal pain, headache, pain in children, acute migraine attack. 
MECHANISM OF ACTION: 
 Nonsteroidal anti-inflammatory drugs such as ibuprofen work by 
inhibiting the cyclooxygenase (COX) enzymes, which convert arachidonic acid to 
prostaglandin H2(PGH2).PGH2 in return, is converted by other enzymes to 
several other prostaglandins (which are mediators of pain, inflammation and 
fever) and to thromboxane A2 (which stimulates platelets aggregation, leading to 
the formation of blood clots). 
 Like aspirin and indomethacin, Ibuprofen is a non -selective COX 
inhibitor, in that inhibits two isoforms of cyclooxygenase, COX-1 and COX-2.The 
analgesic, antipyretic, and anti-inflammatory activity of NSAIDs appear to 
operate mainly through inhibition of COX-2,which decreases the synthesis of 
prostaglandins involved in mediating inflammation ,pain, fever and swelling. The 
antipyretic effects may arise as a result of action on the hypothalamus leading to 
vasodilation, an increased peripheral blood flow and subsequent heat dissipation. 
Inhibition of COX-1 instead would be responsible for unwanted effects on the 
gastro intestinal tract. However the role of the individual COX isoforms in the 
analgesics, anti-inflammatory and gastric damage effects of NSAIDs is uncertain 
and different compounds cause different degree of analgesia and gastric damage. 
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 Ibuprofen is administered as a racemic mixture. The R-enantiomer 
undergoes extensive interconversion to the S- enantiomer in-vivo. The S 
enantiomer is believed to be the more pharmacologically active enantiomer. The R 
enantiomer is converted through a serious of 3 main enzymes. These enzyme 
includes acyl-CoA-synthetase, which converts the R enantiomer to (-)-R-
Ibuprofen 1-CoA;2-arylpropinyl-CoA epinerase, which coverts (-)-R-Ibuprofen 1-
CoA TO (+)-S-Ibuprofen 1-CoA; and hydrolyse, which converts (+)-S-
Ibuprofen1-CoA to the S- enantiomer. In addition to the conversion of ibuprofen 
to the S enantiomer, the body can metabolize Ibuprofen to several other 
compounds, including numerous hydroxyl, carboxyl, and glucuronyl metabolites. 
Virtually all of these have no pharmacological effects.22, 24                                      
CATEGORY: 
    Anti-inflammatory, Analgesic, and Antipyretic 
PHARMACOKINETIC DATA: 
           Bioavailability        : 80-100% [by mouth], 87% [rectal]        
            Protein binding      : 98% 
           Metabolism            :  Hepatic [CYP2C9] 
           Half-life                 : 1.8-2hrs 
           Excretion               : Renal [95%] 
CONTRA INDICATIONS: 
            Hypersensitivity (including asthma; angioedema; urticarial or rhinitis) to 
acetylsalicylic acid or any other NSAID; active peptic ulceration; for treatment of 
pre-operative pain in the setting of coronary artery bypass graft surgery; neonates 
with congenital heart disease. 
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INTERACTION: 
            Drinking alcohol when taking Ibuprofen may increase the risk of stomach 
bleeding. According to the US Food and drug administration (FDA), “Ibuprofen 
can interfere with the antiplatelet effect of low-dose aspirin less effective when 
used for cardio protection and stroke prevention.” Allowing sufficient time 
between doses of ibuprofen and immediate-release (IR) aspirin can avoid this 
problem. The recommended elapsed time between a dose of ibuprofen and a dose 
of aspirin depends on which is taken first, It would be 30 minutes or more for 
ibuprofen taken before IR aspirin. However this timing cannot be recommended 
for enteric coated aspirin. But, if ibuprofen is taken only occasionally without the 
recommended timing, the reduction of the cardio protection and stroke prevention 
of a daily aspirin regimen is minimal. 
ADVERSE EFFECT  
          Gastrointestinal disturbances including nausea, diarrhoea, dyspepsia, 
gastrointestinal  haemorrhage; hypersensitivity reaction including rash 
angioedema; bronchospasm; headache; dizziness; nervousness; depression; 
drowsiness; insomnia; vertigo; tinnitus; photosensitivity; haematuria; renal failure; 
fluid retention(rarely, precipitating congestive failure in elderly), raised blood 
pressure; rarely, hepatic damage; alveolitis, pulmonary eosinophilia; pancreatitis; 
visual disturbance, skin reaction like dermatitis. 
OVER DOSE: 
          Ibuprofen overdose has become common since it was licensed for OTC use. 
Many overdose experiences are reported in the medical literature, although the 
frequency of life threatening complications from ibuprofen overdose is low. 
Human response in cases of overdose ranges from absence of symptoms to fatal 
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outcome despite intensive-care treatment. Most symptoms are an excess of the 
pharmacological action of the ibuprofen, and include abdominal pain, nausea, 
vomiting, drowsiness, dizziness, headache, tinnitus, and nystagmus. Rarely, more 
severe symptoms such as gastrointestinal bleeding, seizures, metabolic acidosis, 
hyperkalaemia, hypotension, bradykardia, tachycardia, atrial fibrillation, coma, 
hepatic dysfunction, acute renal failure, cyanosis, respiratory depression and 
cardiac arrest have been reported. The severity of symptoms varies with the 
ingested dose and the time elapsed; however, individual sensitivity also plays an 
important role. Generally the symptoms observed with an overdose of ibuprofen 
are similar to the symptoms caused by overdoses of other NSAIDs.   
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                                       EXCIPIENTS PROFILE 
 
LACTOSE MONOHYDRATE 
Nonproprietary Names 
      BP       : Lactose 
      JP        : Lactose Hydrate 
      PhEur  : Lactose monohydrate 
      USPNF: Lactose monohydrate 
 
Synonyms 
        Lactochem, Pharmatose, HMS, NF Lactose, capsuLac, PrismaLac, SacheLac, 
Sorbolac, SpheroLac, Tablettose, Inhalac.27 
Chemical Name:  
            O-β-D-Galactopyranosyl-(1-4)-𝛼-D-glucopyranose monohydrate 
Structural Formula: 
 
                                Figure 6: Structure of Lactose monohydrate 
 
Empirical Formula and Molecular Weight: 
           C12H22O11H2O          360.31 
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Description: 
           White crystalline particles or powder. Lactose is odourless and slightly 
sweet-tasting.  
Functional category 
            Binding agent; diluent for dry-powder inhalers; tablet binder; tablet and 
capsule diluent. 
Pharmaceutical Application: 
         27 Lactose is widely used as filler or diluents in tablets and capsules, and to a 
more limited extent in lyophilized products and infant formulas. Lactose is also 
used as a diluents in dry –powders inhalation. various lactose are commercially 
available that have different physical properties such as particle size distribution 
and flow characteristics .This permits the selection of the most suitable material 
for a particular application; for example, the particle size range selected for 
capsules is often dependent on the type of encapsulating machine used. Usually, 
fine grades of lactose are used in the preparation of tablets by the wet-granulation 
method or when milling during processing is carried out, since the fine size 
permits better mixing with other formulation ingredients and utilize the binder 
more efficiently. 
 Other application of lactose includes use in lyophilized products, where 
Lactose is added to freeze-dried solutions to increase plug size and aid cohesion. 
Lactose is also used in combination with sucrose to prepare sugar-coating 
solutions. 
 Direct-compression grades of lactose monohydrate are available as 
granulated/ agglomerated α-lactose monohydrate, containing small amounts of 
anhydrous lactose. 
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 Direct – compression grades are often used to carry lower quantities of 
drug and this permits tablets to be made without granulation. 
 Other directly compressible lactose is spray-dried lactose and anhydrous 
lactose. 
Incompatibilities: 
         A Mail lard-type condensation reaction is likely to occur between lactose 
and compounds with a primary amine group to form brown, or yellowish-brown-
colored products. 
 Lactose is also incompatible with amino acids, aminophylline, 
amphetamines, and lisinopril. 
Storage: 
   Lactose should be stored in a well-closed container in a cool, dry place. 
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POVIDONE 
Nonproprietary Names: 
 BP       : Povidone 
 JP        :  Povidone 
 PhEur :Povidone 
 USP     : Povidone 
Synonyms: 
 Kollidon, Plasdone, Polyvinyl Pyrrolidone, Povidonum,povipharm 
Empirical Formula and Molecular Weight 
 [C6H9NO]n                 2500-3000000  
Chemical Name: 
 -Ethenyl-2-Pyrrolidinone homopolymer 
 
Structural Formula: 
 
                                              Figure 7: Structure of Povidone 
 
Description: 
 Povidone occurs as a fine, white to creamy-white colored, odorless or 
almost odorless, hygroscopic powder. 
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Functional Category: 
 Disintegrant, dissolution enhancer, suspending agent, tablet-binder. 
Pharmaceutical Application: 
 Povidone is used in a variety of pharmaceutical formulations; it’s primarily 
used in solid-dosage forms. In tableting, povidone solutions are used as binders in 
wet-granulation processes. 
 Povidone is additionally used as a suspending, stabilizing or viscosity-
increasing agent in a number of topical and oral suspensions and solutions. 
Solubility: 
 Freely soluble in acids, chloroform, ethanol, ketones, methanol, and water. 
Storage: 
 Povidone stored under ordinary conditions, without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, it 
should be stored in an airtight container in a cool, dry place.27  
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Hydroxy Propyl Methyl Cellulose 
Nonproprietary Names: 
           BP      : Hypromelleose 
           JP       : Hypromellose 
           PhEur : Hypromellose 
           USP    : Hypromellose 
 
Synonyms: 
             Benecel MHPC; E464; hydroxyl propyl methylcellulose; HPMC; 
Methocel; methylcellulose propylene glycol ether ; methyl hydroxy propyl 
cellulose; Metolose; Tylopur. 
 
Chemical Name:  
            Cellulose hydroxyl propyl methyl ether 
 
Structural Formula: 
 
 
                                     Where R is H, CH3 or [CH3CH(OH)CH2] 
                              Figure 8: Structure of hydroxyl propyl methyl cellulose 
 
Molecular weight 
           Molecular weight is approximately 10000-1500000 
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 Description: 
           Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
Functional Category: 
            Coating agent; film-former; rate-controlling polymer for sustained release; 
stabilizing agent; suspending agent; tablet binder; viscosity- increasing agent. 
Pharmaceutical Application: 
            Hypromellose is widely used in oral, ophthalmic and topical 
pharmaceutical formulations. In oral products, hypromellose is primarily used as a 
tablet binder; in film coating, and as a matrix for use in extended-release tablet 
formulations. Concentrations between 2% and 5% w/w may be used as a binder in 
either wet-or dry- granulation processes. High viscosity grades may be used to 
retard the release of drugs from a matrix at levels of 10-80% w/w in tablets and 
capsules. 
 Hypromellose is also used in emulsifier, suspending agent, and stabilizing 
agent in topical gel and ointments. As a protective colloid, it can prevent droplets 
and particles from coalescing or agglomerating, thus inhibiting the formation of 
sediments. 
 In addition, hypromellose is used in the manufacture of capsules, as an 
adhesive in plastic bandages, and as a wetting agent for hard contact lenses. It is 
also widely used in cosmetics and food products. 
 
Viscosity: 
               Different ranges of viscosity grades are available commercially. 
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Table 2: Grades of Hypromellose 
Methocel product Nominal  viscosity(mPas) 
Methocel k100 premium LVEP 100 
Methocel k4M premium 400 
Methocel k15M premium 15000 
Methocel k100M premium 100000 
 
Incompatibilities: 
              Hypromellose is incompatible with some oxidizing agents. Since it is 
Non-ionic, hypromellose will not complex with metallic salts or ionic organics to 
form insoluble precipitates. 
Storage: 
        Hypromellose powder should be stored in a well-closed container, in a cool, 
dry place.27 
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COLLOIDAL SILICON DIOXIDE 
Nonproprietary Name: 
 BP      : Colloidal Anhydrous silica 
 JP       :  Light Anhydrous silicic acid 
 PhEur :  Silica colloidal Anhydrous 
 USP    :  Colloidal silicon Dioxide 
 
Synonyms: 
 Aerosil, colloidal silica, fumed silica, fumed silicon Dioxide 
 
Chemical Name: 
 Silica 
Empirical formula and molecular weight: 
    Sio2                                60.08 
 
Description: 
  It is a light, bluish-white-colored, odorless, tasteless, amorphous powder. 
Functional category: 
 Adsorbent, anticaking agent, emulsion stabilizer, glidant, suspending 
agent, tablet disintegrant, thermal stabilizer, viscosity-increasing agent. 
Pharmaceutical Application: 
 Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and 
food products.27 
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MAGNESIUM STEARATE 
Nonproprietary Name: 
 BP       :Magnesium stearate 
 JP        :Magnesium stearate 
 PhEur   :Magnesium Stearate 
 USP      :Magnesium stearate 
Synonyms: 
 Magnesium octadecanoate; octadecanoic acid; magnesium salt; stearic 
acid. 
Chemical Name:  
 Octadecanoic acids magnesium salt 
Empirical Formula and Molecular Weight: 
 C36 H70Mgo4                         591.34 
 
Structural formula: 
 
Figure 9: Structure of Magnesium Stearate 
Functional Category: 
       Tablet and capsule lubricant. 
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Pharmaceutical Application: 
 Magnesium stearate is widely used in cosmetics, foods, and 
pharmaceutical formulation. It is primarily used as a lubricant in capsule and 
tablet manufacture at concentrations between 0.25% and 5.0%W/W. It is also used 
in barrier creams. 
Incompatibilities 
 Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with 
strong oxidizing materials. Magnesium stearate cannot be used in products 
containing aspirin, some vitamins, and most alkaloidal salts.27 
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BETA-CYCLODEXTRIN 
Nonproprietary Names: 
     BP        :  Alfadex Betadex 
    PhEur   :  Alfadex Betadex 
     USP     :  Alfadex Betadex 
 
Synonyms: 
      Beta-cyclodextrin, beta-cycloamylose, beta-dextrin, cyclomaltoheptose, 
beta dexum. 
 
Chemical Name: 
 Cyclohepta amylose 
 
Empirical formula and Molecular weight: 
 C42H70O35                  113 
  
Structural Formula: 
 
Figure 9: Structure of Beta-Cyclodextrin 
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 Description: 
 Cyclodextrins occurs as white, practically odorless, fine crystalline 
powders, having a slightly sweet taste. 
Functional category: 
      Encapsulation agent  
      Used for increasing the solubility of poorly soluble drugs.   
 Pharmaceutical Application: 
 It can be applied widely in the production of medicine, food and 
cosmetics. 
Solubility: 
 Sparingly soluble in water 
 Freely soluble in hot water 
 Slightly soluble in ethanol 
Storage: 
 Stored in a well closed air tight container.27 
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MATERIALS AND INSTRUMENTS 
Table 3: MATERIALS 
S.No. Materials Manufacture 
1. Ibuprofen Sun Pharmaceuticals 
2. Lactose monohydrate Hi media Laboratories 
3. Kollidon SR S.D. Fine Chemicals 
4. HPMCK100MCR Vijlak Pharma,A.P. 
5. HPMCK4MCR Vijlak Pharma.A.P. 
6. Aerosil S.D. Fine Chemicals 
7. Magnesium Stearate S.D. Fine Chemicals 
8. Beta cyclodextrin SD Fine chemicals 
9 PEG 6000 S.D. Fine Chemicals 
 
Table 4: INSTRUMENTS 
S.No. Instruments Manufacture 
1. Analytical Balance Dhona 200D 
2. FTIR Spectrophotometer Jasco FT-IR 8201 PC 
3. Dissolution Apparatus Electro lab TDT-08L 
4. Compression Machine Rimek Mini Press 
5. Differential Scanning Calorimetry Perkin Elmer, Pyris 6 DSC, Germany 
6. Vernier Caliper Aerospace 0.2 mm 
7. Hardness Tester Pfizer Hardness Tester 
8. Friabilator Roche Friabilator 
9. UV Spectrophotometer Jasco V530 
10. Disintegration test Apparatus Electrolab disintegrator 
11. Hot air oven Thermolab 
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EXPERIMENTAL SECTION                                           
ANALYTICAL METHOD  USED FOR ESTIMATION OF IBUPROFEN 
BY UV SPECTROPHOTOMETRY  
 
Preparation of Calibration Curve of Ibuprofen in pH 7.2 Phosphate buffer 
by using the UV method 
 100mg of ibuprofen was weighed and transfer into a 100ml of volumetric 
flask and was dissolved in phosphate buffer of pH7.2 and make up to 100ml.  This 
was the standard stock solution containing 1mg/ml of ibuprofen.  From this stock 
solution 10ml was taken and made up to 100ml with phosphate buffer pH 7.2.  
This was the second standard stock solution (100µg/ml).  From this solution 
dilutions of 10µg/ml, 20µg/ml, 30µg/ml, 40µg/ml, 50µg/ml were made and 
absorbance was measured at 222nm. 
PRE FORMULATION STUDIES 
Fourier Transform Infrared (FTIR) studies 
 The compatibility of drugs and excipients used under experimental 
condition were studied. The study was performed by taking 2mg sample in 200 
mg KBr (Jasco FT-IR8201 PC). The scanning range was 400 to 4000 cm-1 and the 
resolution was 1cm-1. This spectral analysis was employed to check the 
compatibility of drugs with the excipients used.   
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Differential Scanning Calorimetry (DSC) 
 The differential scanning calorimetry (DSC) of pure drugs, solid 
dispersion, and the physical mixture of the drug was performed using DSC 
instrument (Perkin Elmer Pyris 6 DSC, Germany), for the measurement of heat 
loss or gain resulting from physical or chemical changes within the sample as a 
function of temperature. About 6-7 mg of the sample was weighed in aluminium 
DSC pans and hermetically sealed with aluminium lids. An initial ramp was used 
to jump the temperature to 30ºC and then a constant heating rate of 10ºC/min was 
used up to 400ºC under nitrogen temperature.     
Formulation Development 
Preparation Solid dispersion of Ibuprofen 
          Preparation of solid dispersions of Ibuprofen is to improve the solubility of 
Ibuprofen and dissolution rate. Solid dispersion of Ibuprofen was prepared by 
solvent evaporation method. The drug and carrier were mixed in 1:1, 1:2 and 1:3 
ratios in ethanol. Solvent was removed by evaporation under reduced pressure. 
The mass was pulverised and passed through sieve no 60 and stored.   
Preparation of physical mixture containing Ibuprofen 
   The physical mixtures of Ibuprofen-PEG 6000 and Ibuprofen –                   
β -Cyclodextrin in the same weight ratio (1:3) were prepared by thoroughly mixing 
the appropriate amount of two components for 10 min in a mortar. The mixtures 
were sieved through a 60 mesh screen and stored in a desiccator for further 
evaluation. The method of preparation and composition were given Table5. 
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            Table 5: Composition of various batches of Physical mixtures  
                                       and Ibuprofen Solid Dispersion 
Batch Code Composition Ratio 
P.M1 Ibuprofen: β-Cyclodextrin 1:3 
P.M2 Ibuprofen: PEG 6000 1:3 
S.D β1 Ibuprofen: β-Cyclodextrin 1:1 
S.D β2 Ibuprofen: β-Cyclodextrin 1:2 
S.D β3 Ibuprofen: β-Cyclodextrin 1:3 
S.D P1 Ibuprofen: PEG 6000 1:1 
S.D P2 Ibuprofen: PEG 6000 1:2 
S.D P3 Ibuprofen: PEG 6000 1:3 
    
Evaluation of Ibuprofen solid dispersions and physical mixtures 
     Evaluation studies were carried out by estimating drug content and in vitro 
dissolution studies. 
Drug content 
      The drug content of each solid dispersion batch and physical mixture were 
determined by UV-spectrophotometry. Accurately weighed quantity of samples 
from all batches equivalent to 100 mg of Ibuprofen was transferred to a 100ml 
volumetric flask containing 100ml of phosphate buffer pH 7.2 and the absorbance 
was measured at 222nm. 
In vitro dissolution studies  
      The prepared solid dispersions were accurately weight equivalent to 
100mg of the drug. These solid dispersions are filled in empty capsules and 
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analysed for drug release in 900ml of phosphate buffer pH (7.2) as dissolution 
medium at 37± 0.5ºC and 50rpm. 5ml of the sample solution was taken from the 
dissolution apparatus and the same volume replaced with fresh dissolution 
medium at predetermined time intervals for 5min. The absorbance of these 
solutions was measured at 222nm using UV-Visible spectrophotometer.     
Preparation of sustained release tablet by using Ibuprofen solid dispersion 
 Ibuprofen sustained release tablets were prepared by the wet granulation 
method. Weigh equivalent mg of solid dispersion of Ibuprofen, with other 
tableting excipients. The blend was mixed with various concentration of rate 
controlling polymer like HPMC K4MCR, HPMCK100MCR with binder solution. 
Then the prepared wet mass was passed through Sieve No:60 and dried. The dried 
granules were mixed with lubricant and compressed into sustained release tablets 
each weighing about 600mg, by using 12mm punch.  
               Table 6: Composition of Ibuprofen Sustained release trial tablets  
Composition 
F1IB 
(mg) 
F2IB  
(mg) 
F3IB  
(mg) 
F4IB 
(mg) 
F5IB 
(mg) 
F6IB 
(mg) 
F7IB 
(mg) 
F8IB 
(mg) 
F9IB 
(mg) 
F10IB 
(mg) 
SD[400mg 
of 
Ibuprofen] 
480 480 480 480 480 480 480 480 480 480 
Lactose 
monohydrate 
30 40 30 20 40 40 30 20 40 30 
Kollidon SR 20 20 30 10 30 20 10 20 30 40 
HPMC 
K4MCR 
60 - 50 50 40 - 40 50 - 40 
HPMC     
K100MCR 
- 50 - 30 - 50 30 20 40 - 
Magnesium 
stearate 
2 2 2 2 2 2 2 2 2 2 
Aerosil 8 8 8 8 8 8 8 8 8 8 
Total 600 600 600 600 600 600 600 600 600 600 
 *All the ingredients in mg 
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                     Figure 11: Composition of Ibuprofen Sustained release trial tablets 
Evaluation of Pre Compression Parameters 
 The flow properties of the granules were evaluated by determining angle 
of repose, Bulk density, Tapped density, Compressibility index and Hauser’s ratio 
as mentioned below.34, 35 
Angle of repose(Ɵ)                     
               Angle of repose is the tan inverse of angle between height (h) of pile of 
powder and the radius (r) of the base of conical pile. It can be obtained between 
the freestanding surface of the powder heap and the horizontal plane. The fixed 
funnel that is secured with its tip at a given height h, above graph paper, placed on 
the flat horizontal surface. Powder is carefully poured through funnel until the 
apex of conical pile just touches the tip of funnel.                                                            
                                                ϴ =tan-1 (h/r) 
                                                Where,  
                                                ϴ= the angle of repose                                                     
                                                h = height of pile 
                                                  r = radius of base of the pile   
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Table 7: Relationship between Angle of repose(Ɵ) and Flow properties 
Angle of repose(Ɵ) Flow 
25-30 Excellent 
30-45 Good 
35-40 Fair 
40-45 Poor 
45-50 Very poor 
 
Bulk density and Tapped density 
 Both loose bulk density and tapped bulk density were determined. A 
quantity of 2gm of granules from each formula previously light shaken for the 
break of any agglomerates formed was introduced into the 10ml of measuring 
cylinder. After the initial volume was observed, the cylinder was allowed to fall 
down its own weight from the hard surface from a height of 2-5cm at 2sec 
intervals. The tapping was continued until no further change in the volume was 
noted. 
                  LBD and TBD were calculated using the following formula: 
                  LBD: weight of the powder/volume of the packing 
                  TBD: weight of the powder/Tapped volume of the packing 
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Compressibility index 
 The compressibility index of the granules was determined by Carr’s 
compressibility index. (%) carr’s index can be calculated by using the following 
formula       
                  Carr’s index (%) = [(TBD-LBD) X100]/TBD 
                  Where, 
                  LBD: weight of the powder/volume of the packing 
                 TBD: weight of the powder/Tapped volume of the packing 
Table 8:  Grading of the powders for their flow properties according to             
Carr’s index 
Carr’s Index(%) Flow 
5-15 Excellent 
12-16 Good 
18-21 Fair 
23-25 Poor 
35-38 Very poor 
More than 40 Extremely poor 
 
Hausner’s Ratio: 
      Hausner’s Ratio is used to express the compressibility of the powder. It was 
calculated using the formula 
                          Hausner’s Ratio= Tapped Density/Bulk Density  
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Table 9: Grading of the powders for their flow properties according 
 to Hausner’s Ratio 
Hausner’s Ratio Flow 
1.00-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.59 Very poor 
>1.60 Very, very poor 
 
Evaluation of Post Compression Parameters 
          The formulated tablets tablets were evaluated for the following 
parameters.37 
1.  General appearance 
    The general appearance of tablets, its visual identify and overall ‘elegance’ 
is essential for consumer acceptance for monitoring the production process. 
Size and Shape: 
            The shape and dimensions of compressed tablets are determined by the 
type of tooling during the compression process. 
2. Uniformity of Thickness 
        The crown thickness of individual tablet may be measured with a vernier 
caliper, which permits accurate measurements and provides information on the 
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variation between tablets. Other technique employed in production control 
involves placing 5or 10 tablets in a holding tray, where their total crown thickness 
may be measured with a sliding caliper scale. The tablet thickness was measured 
using screw gauge.   
 3.  Hardness test 
 The hardness of the tablets was determined using Pfizer Hardness tester. It 
is expressed in kg/cm3 six tablets were randomly picked from each formulation 
and the mean and standard deviation values were calculated. 
4.  Friability 
 The friability of tablets was determined using Roche Friabilator. It is 
express in percentage (%). Ten tablets were initially weighed and revolved at 
25rpm for 4min. the tablets were then reweighed after removal of fines and the 
percentage of weight loss was calculated by, 
                         %Friability = Initial weight-Final weight×100 
                                                       Initial weight                
 5.  Weight Variation 
      Twenty tablets were selected randomly from each batch and weighed 
individually on electronic balance. The individual weighed is then compared with 
average weight for the weight variations. The following percentage deviation in 
weight variation is allowed. The results are shown in Table10. 
     % Deviation= Average weight- Individual weight/Average weight×100 
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Table 10: Percentage weight deviations 
Average weight % difference 
130mg or less 10 
130-324mg 7.5 
324mg and greater 5 
 
6.  Drug content Uniformity  
 Twenty tablets were weighed and its average weight was taken, the 
powder equivalent to single tablet was dissolved in pH 7.2 phosphate buffer and 
was transferred to a100ml volumetric flask. After adequate dilutions the 
absorbance was measured at 222nm.Samples were analyzed by using UV-
Spectrophotometer. 
7.  In-vitro dissolution rate studies 
 The dissolution studies of the Ibuprofen SR tablets were performed using 
USP dissolution testing apparatus II (paddle type). Using 900ml of phosphate 
buffer pH 7.2 was taken as the dissolution medium at 37±0.5ºC and 50rpm. 5ml of 
the sample was taken from the dissolution apparatus at predetermined time 
intervals for 24 hrs. The samples were replaced with the same quantity of 
medium. Absorbance of these solutions was measured at 222nm using UV 
Spectrophotometer. The concentration of the drug released at different time 
interval was determined from standard graph. From this cumulative % drug 
release was calculated and this was plotted against function of time to find out the 
pattern of drug release. The rates of the drug released were determined. 
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8.  Drug Release Kinetics 
 Drug release kinetics was performed using model dependent method in 
which the dissolution profile of each formulation has been subjected various 
kinetics like zero order, first order, Higuchi’s and korsmeyer-Peppas model.44,45,46 
 The data obtained from in vitro drug release studies were plotted in various 
kinetic models; as mentioned below zero order (Equation 1) as cumulative amount 
of drug released vs time, first order ( Equation 2) as log as cumulative percentage 
of drug remaining vs time, and Higuchi’s model (Equation 3)as cumulative 
percentage of drug released vs square root of time. 
   Qt = Q0+k0t                                                     (Equation 1) 
        Where Qt is the amount of drug dissolved in time t,Q0 is the initial amount of 
drug in the solution and K0 is the zero-order rate constant expressed in units of 
concentration/time and t is the time in hours. A graph of concentration vs time 
would yield a straight line with a slope equal to K0 and intercept the origin of the 
axis. 
           LogC =logCO-kt/2.303                              (Equation 2) 
        Where C0 is the initial concentration of drug is the first order constant, and t 
is the time. 
  Qt=KHt½                         (Equation 3) 
         Where KH is the constant reflecting the design variables of the system and t 
is the time in hours. Hence drug release rate is proportional to the reciprocal of the 
square root of time. Drug release were plotted in korsmeyer equation (Equation 4) 
as log cumulative percentage of drug released vs log time, and the exponent n was 
calculated through the slope of the straight line. 
   Mt/M∞=Ktn                             (Equation 4) 
Where Mt/M∞ is the fractional solute release, t is the release time, K is a kinetic 
constant. 
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Table 11: Diffusion Exponent and Solute Release Mechanism 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n<0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n>0.89 Super case-II transport 
 
9. Stability studies 
         Stability study was carried out to observe the effect of temperature and 
relative humidity on selected formulation (F7), by keeping at 40±2ºC, in air tight 
high density polyethylene bottles for six months, at RH 75±5%. Physical 
evaluation was carried out in each month.81 
Table 12: ICH guidelines for Stability study 
Study Storage condition Time period 
Long term 25ºC±2ºC/60%RH±5%RH 12month 
Intermediate 30ºC±2ºC/65%RH±5%RH 6 month 
Accelerated 40ºC±2ºC/75%RH±5%RH 6 month 
     
     
     
 
Results & Discussion 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique 77 
RESULTS AND DISCUSSION 
Preparation of Calibration curve for Ibuprofen 
  The calibration curve of Ibuprofen was drawn by measuring the 
absorbance of different concentrations in phosphate buffer pH 7.2 at 222nm. The 
calibration curve obtained is shown in Table 13 and figure 12. 
Table 13: Calibration curve of Ibuprofen 
SI.No. Concentration(µg/ml) Absorbance(222nm) 
1. 0 0 
2. 10 0.151 
3. 20 0.351 
4. 30 0.521 
5. 40 0.713 
6. 50 0.912 
 
 
 
 
 
 
Figure 12: Calibration curve of ibuprofen 
 The calibration curves were linear and obeyed Beer-Lambert’s law in the 
concentration range 10-50μg/ml. The correlation coefficient values were 0.9986 
indicating excellent linearity of the data. 
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DRUG-EXCIPIENTS COMPATIBILITY STUDIES 
Fourier Transform Infrared Studies 
 The FTIR Spectra of Ibuprofen in pure form and their physical mixture 
was observed, the result showed that there is no interaction between drug and 
polymers. From the FTIR spectral Figures 13to 21 Interpretations the following 
result was obtained. The FTIR of Ibuprofen and combinations of polymers shows 
intense band in the table 14 to 22 as follows.    
 
                                Figure 13: FTIR Spectrum of Ibuprofen 
                                       Table 14: Interpretation of Ibuprofen 
Wave number cm-1 Probable functional group 
788.89 C-H bending   (aro) 
1411.89 C=C stretching(aro) 
1550.7 C=O stretching (acid) 
2954.95 C-H stretching (alkane) 
3365.78 O-H stretching 
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                   Figure 14: FTIR Spectrum of Ibuprofen+ Lactose monohydrate 
Table 15: Interpretation of Ibuprofen+ Lactose monohydrate 
Wave number cm-1 Probable functional group 
779.24 C-H bending   (aro) 
1415.7 C=C stretching(aro) 
1550.77 C=O stretching (acid) 
2899.01 C-H stretching (alkane) 
3325.28 O-H stretching 
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Figure 15:FTIR Spectrum of Ibuprofen+ Kollidon SR 
Table 16: Interpretation of Ibuprofen+ Kollidon SR 
Wave number cm-1 Probable functional group 
846.75 C-H bending   (aro) 
1417.68 C=C stretching(aro) 
1639.49 C=O stretching (acid) 
2954.95 C-H stretching (alkane) 
3415.93 O-H stretching 
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Figure 16: FTIR Spectrum of Ibuprofen+ HPMC K4 MCR 
Table 17: Interpretation of Ibuprofen+ HPMC K4MCR 
Wave number cm-1 Probable functional group 
617.22 C-H bending   (aro) 
1415.75 C=C stretching(aro) 
1620.21 C=O stretching (acid) 
2954.92 C-H stretching (alkane) 
3415.93 O-H stretching 
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Figure 17: FTIR Spectrum of Ibuprofen+ HPMC K100 MCR 
Table 18: I Interpretation of Ibuprofen+ HPMC K100MCR 
Wave number cm-1 Probable functional group 
684.43 C-H bending   (aro) 
1468.56 C=C stretching(aro) 
1620.21 C=O stretching (acid) 
2922.16 C-H stretching (alkane) 
3415.93 O-H stretching 
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Figure 18:FTIR Spectrum of Ibuprofen+ Magnesium stearate 
Table 19: Interpretation of Ibuprofen+ Magnesium stearate 
Wave number cm-1 Probable functional group 
621.08 C-H bending   (aro) 
1463.97 C=C stretching(aro) 
1616.35 C=O stretching (acid) 
2918.30 C-H stretching (alkane) 
3414.00 O-H stretching 
Results & Discussion 
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Figure 19:FTIR Spectrum of Ibuprofen+ Aerosil 
 
Table 20: Interpretation of Ibuprofen+ Aerosil 
Wave number cm-1 Probable functional group 
                   788.89 C-H bending   (aro) 
1413.82 C=C stretching(aro) 
1550.77 C=O stretching (acid) 
2954.95 C-H stretching (alkane) 
3415.93 O-H stretching 
 
Results & Discussion 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique 85 
        
Figure 20: FTIR Spectrum of Ibuprofen+ Beta cyclodextrin Solid Dispersion 
                      
Table 21: Interpretation of Ibuprofen+ Beta cyclodextrin Solid dispersion 
Wave number cm-1 Probable functional group 
607.58 C-H bending   (aro) 
1409.96 C=C stretching(aro) 
1618.28 C=O stretching (acid) 
2924.09 C-H stretching (alkane) 
3414.00 O-H stretching 
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                           Figure 21: FTIR Spectrum of Ibuprofen tablet 
Table 22: Interpretation of Ibuprofen tablet 
Wave number cm-1 Probable functional group 
848.68 C-H bending   (aro) 
1409.96 C=C stretching(aro) 
1616.35 C=O stretching (acid) 
2924.09 C-H stretching (alkane) 
3414 O-H stretching 
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Differential Scanning Calorimetry (DSC) 
 The compatibility and interactions between drugs and polymers were 
checked using DSC results obtained were shown in figure 22 to 23. 
     
 
 
 
 
 
 
 
Figure 22: Differential Scanning Calorimetry of Ibuprofen 
 
 
 
 
 
 
Figure 23: Differential Scanning Calorimetry of  
Ibuprofen + β-Cyclodextrin Solid dispersion 
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 The DSC thermogram of pure Ibuprofen showed a sharp endothermic peak 
at 100.00ºC which corresponds to its melting point. The DSC thermogram of 
Ibuprofen-β-Cyclodextrin(1:3) solid dispersion prepared by a solvent evaporation 
method (SDβ3) showed endothermic peak at temperature 80.94ºC with some 
changes in the characteristics of the peaks. It showed that no possible interaction 
took place between the drug and carriers.  
 Evaluation of Ibuprofen solid dispersions and physical mixtures 
 Evaluation of drug content 
         The drug content of each solid dispersion batch and physical mixture were 
determined by UV-spectrophotometry measured at 222nm. 
 
Table 23: Drug content of evaluation of solid dispersion containing Drug and 
Carriers for various formulations 
Batch code % Drug content ±S.D 
PM1 95±0.42 
PM2 93±0.16 
S.Dβ1 90±0.18 
S.Dβ2 95±0.78 
S.Dβ3 99±0.83 
S.DP1 91±0.74 
S.DP2 92±0.84 
S.DP3 93±0.74 
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In vitro drug release study of solid dispersion containing Drug and carriers 
for various formulations 
Table 24: In vitro drug release study of solid dispersion containing Drug and 
carriers for various formulations 
Time 
(min) 
Cumulative Percentage of Drug Released ± S.D 
P.M1 P.M2 S.Dβ1 S.D β2 S.D β3 S.D P1 S.D P2 S.D P3 
0 0 0 0 0 0 0 0 0 
5 10±0.27 11±0.26 10±0.11 13±0.15 12±0.13 10±0.16 10±0.11 12±0.12 
10 23±0.32 20±0.34 12±0.12 22±0.37 20±0.32 23±0.22 20±0.54 24±0.45 
15 45±0.33 34±0.24 16±0.24 30±0.22 23±0.63 31±0.34 28±0.22 29±0.27 
20 50±0.24 46±0.32 20±0.14 40±0.68 30±0.24 52±0.18 35±0.33 32±0.36 
25 53±0.67 53±0.63 27±0.23 52±0.35 36±0.16 70±0.16 46±0.56 38±0.24 
30 59±0.63 64±0.34 33±0.88 60±0.54 48±0.34 74±0.14 50±0.38 46±0.28 
35 64±0.62 76±0.48 38±0.54 67±0.18 52±0.25 79±0.18 63±0.13 56±0.44 
40 69±0.54 80±0.26 42±0.82 70±0.17 67±0.23 84±0.20 68±0.26 64±0.83 
45 73±0.36 83±0.36 50±0.24 72±0.19 78±0.26 88±0.23 74±0.16 73±0.56 
50 79±0.42 88±0.24 63±0.56 80±0.17 80±0.48 90±0.18 84±0.22 86±0.38 
55 82±0.64 90±0.38 72±0.58 86±0.19 92±0.16 93±0.27 89±0.43 90±0.22 
60 86±0.62 92±0.42 80±0.88 90±0.38 98±0.32 96±0.30 93±0.26 95±0.32 
Each value was an average of six determinations (n=6) ± S.D (Standard 
Deviation) 
Results & Discussion 
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Figure 24: In vitro drug release study of solid dispersion containing Drug and 
Carrier for various formulations 
 
 The solid dispersion of S.D β3 batch showed maximum drug content 
[99±0.83] and drug release [98%] within 60 minutes, among all the formulations 
and this ratio can be used to enhance the solubility and dissolution rate of poorly 
water soluble drug Ibuprofen. It was observed that the drug release was increased 
with increasing the quantity of β-cyclodextrin. 
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Evaluation of Pre-compression of Ibuprofen SR granules 
Table 25: Pre-Compression parameters of Ibuprofen Trial batch F1IB-F10IB 
Formulation 
Code 
Angle of 
Repose(Ɵ) 
Bulk 
Density(gm/cm3) 
Tapped 
Density(gm/cm3) 
Carr’s 
index(%) 
 
Hausner’s                          
ratio 
F1IB 25º.16’±0.14 0.572±0.05 0.640±0.07 10.62±0.28 1.11±0.07 
F2IB 25º.73’±0.57 0.562±0.04 0.634±0.08 10.36±0.32 1.10±0.02 
F3IB 25º.88’±0.06 0.570±0.02 0.627±0.04 11.50±0.56 1.13±0.04 
F4IB 25º.08’±0.12 0.582±0.03 0.624±0.02 11.24±0.45 1.11±0.03 
F5IB 25º.95’±0.36 0.552±0.01 0.654±0.04 11.05±0.36 1.12±0.25 
F6IB 25º.02’±0.54 0.554±.0.03 0.642±0.02 10.84±0.45 1.13±0.23 
F7IB 25º.44’±0.58 0.556±0.02 0.613±0.06 11.60±0.28 1.12±0.08 
F8IB 25º.56’±0.76 0.558±0.04 0.645±0.08 10.56±0.46 1.10±0.04 
F9IB 25º.01’±0.19 0.565±0.08 0.653±0.02 9.75±0.34 1.11±0.28 
F10IB 24º.96’±0.18 0.577±0.04 0.628±0.06 9.92±0.27 1.13±0.24 
All values are mean ± S.D n=3 
  The angle of repose was found to be ranging from 24º96’±0.18 to 
25º95’±0.36 for all formulations. 
  The Bulk density and Tapped density of the prepared blend ranged from 
0.552±0.01 to 0.582±0.03 gm/cm3 and 0.613±0.06 to 0.654±0.04 gm/cm3 
respectively.   
  The Compressibility index was found to ranging from 9.75±0.34 to 
11.60±0.28% 
  The Hausner’s ratio ranged from 1.10±0.02 to 1.13±0.24. The granules are 
having good flow property. 
            From the results of precompression evaluation all the formulations having 
good flowing property and the results are within the pharmacopoeial limit.  
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Evaluation of Post compression parameters of Ibuprofen Sustained  
release tablets 
Table 26: Post-Compression parameters of Ibuprofen Trial batch F1IB – F10IB 
Formulations 
Thickness 
(mm) 
Diameter 
(mm) 
Hardness 
(kg/cm2) 
Friability 
(%) 
Weight 
variation(mg) 
Drug 
Content(%) 
F1IB 4.04±0.02 12±0 4.43±0.58 0.85±0.10 600.3±1.69 96.46±1.05 
F2IB 4.04±0.01 12±0 4.27±0.56 0.84±0.11 600.1±1.68 95.22±1.04 
F3IB 4.06±0.02 12±0 4.42±0.54 0.85±0.12 600.4±1.64 93.13±1.46 
F4IB 4.08±0.01 12±0 4.44±0.78 0.87±0.11 600.0±1.22 94.24±1.22 
F5IB 4.09±0.52 12±0 4.45±0.28 0.86±0.10 600.2±2.14 92.12±0.90 
F6IB 4.07±0.54 12±0 4.48±0.31 0.88±0.11 600.4±1.26 98.14±0.12 
F7IB 4.09±0.02 12±0 4.49±0.32 0.85±0.10 600.0±2.65 99.80±0.48 
F8IB 4.08±0.01 12±0 4.42±0.30 0.84±0.13 600.2±1.43 95.64±0.42 
F9IB 4.05±0.03 12±0 4.40±0.31 0.84±0.12 600.4±1.63 92.64±0.34 
F10IB 4.06±0.01 12±0 4.34±0.35 0.83±0.14 600.3±1.47 90.29±0.52 
All values are mean ±S.D n=3 
 The result of post compression parameters of all formulations are shown in 
table 26. 
 The thickness was ranged between 4.04±0.01mm to 4.09±0.52mm, 
indicating the uniformity in thickness.  
 Diameter for all the formulation was 12±0mm showed there was no 
significance difference. 
  The hardness of all formulation in ranges from 4.27±0.56 to 4.49±0.32 
kg/cm2.   
   The friability was less than 1% indicating good integrity of the tablet. 
   The weight variation of all formulations range from 600.0±1.22 to 
600.0±2.65 mg. The values are within the acceptable range of pharmacopoeial 
specification.  
   The drug content was in the range of 90.29±0.52 to 99.80±0.48% 
indicated good content uniformity.     
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In-vitro Drug Release of Ibuprofen SR Tablets 
Table 27:  In-vitro Drug Release profile data of various formulations of  
Ibuprofen sustained release Tablets 
Time in 
Hours 
Cumulative Percentage of Drug Released ±S.D 
F1IB F2IB F3IB F4IB F5IB F6IB F7IB F8IB F9IB F10IB 
1 
3.86       
±1.00 
4.03           
±1.17 
4.02        
±0.95 
3.46          
±1.00 
4.07          
±0.95 
4.05 
±0.93 
2.66        
±0.12 
2.38 
±0.14 
2.50 
±0.50 
2.26 
±0.34 
2 
12.04 
±0.77 
7.36           
±1.12 
11.25      
±0.68 
12.68        
±0.76 
7.66          
±1.10 
9.64     
±1.08 
4.09       
±0.34 
8.05 
±0.96 
3.74 
±0.14 
4.56 
±0.23 
3 
19.95 
±0.20 
12.81        
±0.07 
22.98      
±1.65 
20.95        
±0.21 
11.81       
±0.07 
13.81   
±0.86 
11.72     
±0.02 
10.56 
±0.54 
11.70 
±0.51 
10.45 
±0.66 
4 
27.67 
±1.26 
14.09       
±0.56 
27.47     
±3.74 
26.67        
±1.20 
13.10       
±0.07 
21.96   
±1.64 
16.34     
±0.92 
14.68 
±0.68 
16.53 
±0.38 
15.46 
±0.24 
5 
30.33 
±0.17 
19.46       
±0.27 
35.20      
±0.06 
29.32       
±1.28 
18.49       
±0.27 
25.47    
±3.46 
18.62     
±0.21 
16.68 
±0.42 
20.36 
±0.08 
18.78 
±0.78 
6 
36.90 
±1.97 
29.64        
±0.41 
38.96     
±0.72 
30.43       
±2.28 
29.66       
±0.41 
32.20   
±0.74 
24.32     
±0.30 
22.28 
±1.75 
25.11 
±0.24 
20.24 
±0.09 
7 
43.49  
±0.31 
32.26        
±2.19 
42.80     
±0.47 
35.20       
±0.07 
32.28       
±2.19 
36.98   
±0.72 
36.34     
±0.11 
25.10 
±0.24 
28.76 
±0.48 
22.78 
±1.64 
8 
44.47 
±1.24 
36.20       
±1.06 
44.43      
±1.24 
38.97       
±0.73 
36.20        
±1.04 
38.97  
±0.73 
44.23     
±0.46 
28.76 
±0.44 
35.60 
±1.41 
26.44 
±3.74 
9 
49.13 
±0.69 
38.71       
±0.17 
49.13      
±0.69 
42.85       
±0.43 
38.70       
±0.16 
40.86  
±0.47 
50.09    
±0.62 
34.20 
±1.43 
37.84 
±0.04 
35.20 
±0.06 
10 
51.45 
±1.24 
41.94       
±2.73 
51.45      
±1.22 
44.47        
±1.22 
41.92        
±2.72 
42.84  
±0.46 
54.90      
±0.17 
46.38 
±0.56 
40.52 
±0.78 
38.97 
±0.73 
11 
54.22 
±0.43 
44.53        
±1.15 
62.40     
±0.64 
48.24         
±0.50 
44.55       
±1.15 
44.47  
±1.24 
58.47     
±0.14 
51.45 
±1.26 
41.45 
±0.46 
42.86 
±0.47 
12 
62.44 
±0.67 
48.44       
±0.51 
66.78      
±0.76 
51.98       
±1.24 
47.49       
±0.51 
49.13  
±0.69 
60.89    
±0.20 
58.61 
±0.43 
44.82 
±1.10 
46.14 
±0.68 
13 
64.91 
±0.84 
50.79       
±0.14 
70.24      
±0.09 
63.43       
±0.73 
50.76        
±0.12 
52.46  
±1.26 
70.25     
±0.80 
62.48 
±0.64 
49.90 
±0.10 
50.44 
±1.26 
14 
65.36 
±0.44 
55.74       
±1.44 
74.85      
±0.58 
65.74       
±0.46 
55.75       
±1.44 
62.44  
±0.67 
74.33     
±0.06 
66.80 
±0.78 
50.34 
±0.42 
58.78 
±0.16 
15 
70.28 
±0.09 
58.40       
±0.42 
80.86      
±0.59 
68.34        
±0.34 
58.38        
±0.42 
68.80   
±0.74 
78.74     
±0.24 
72.85 
±0.58 
53.64 
±0.86 
62.44 
±0.68 
16 
74.85 
±0.58 
60.91        
±0.43 
82.23      
±1.84 
72.66       
±0.58 
60.73       
±0.42 
70.28  
±0.09 
81.24     
±0.46 
78.44 
±0.06 
58.82 
±0.13 
66.80 
±0.76 
17 
76.59 
±1.17 
65.54        
±0.46 
83.62      
±0.64 
77.86        
±1.16 
65.54       
±0.48 
74.82  
±0.56 
88.94     
±0.16 
82.64 
±1.82 
60.18 
±0.41 
71.46 
±0.09 
18 
78.20 
±0.04 
69.74        
±0.12 
87.72      
±0.40 
81.12       
±0.49 
69.76       
±0.14 
80.05   
±0.58 
92.97    
±0.26 
84.42 
±0.68 
65.49 
±0.65 
74.85 
±0.58 
19 
80.06 
±0.59 
73.25       
±0.64 
89.92     
±0.56 
83.68        
±0.66 
72.25        
±0.62 
81.27  
±1.84 
93.01     
±1.00 
88.24 
±0.54 
69.20 
±0.64 
78.86 
±0.57 
20 
81.10 
±0.48 
77.42        
±0.40 
92.26     
±0.10 
86.89        
±0.56 
76.24       
±0.40 
83.63   
±0.68 
93.19     
±0.86 
90.26 
±0.10 
77.25 
±0.25 
82.63 
±0.64 
21 
82.27 
±1.86 
79.22        
±0.41 
93.48     
±0.58 
88.46       
±0.64 
78.24       
±0.41 
87.74  
±0.40 
94.10     
±0.97 
92.36 
±0.10 
80.16 
±0.52 
86.16 
±0.52 
22 
83.63 
±0.65 
81.92       
±0.70 
94.10      
±0.56 
90.64        
±0.88 
81.92        
±0.71 
89.96  
±0.56 
94.97     
±0.74 
93.34 
±0.54 
83.23 
±0.43 
90.26 
±0.12 
23 
87.74 
±0.40 
85.37        
±1.54 
95.78     
±0.53 
92.67       
±0.10 
85.37        
±1.54 
92.26  
±0.12 
95.99     
±0.18 
95.46 
±0.65 
83.36 
±0.27 
93.49 
±0.56 
24 
89.98 
±0.56 
85.81        
±0.73 
96.32      
±0.86 
94.48       
±0.66 
86.81        
±0.73 
93.49  
±0.58 
99.41     
±0.16 
96.91 
±0.28 
 
84.76 
±0.65 
95.68 
±0.76 
Each value was an average of six determinations (n=6)± S.D (standard Deviation) 
Results & Discussion 
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Figure 25: In vitro cumulative (%) Drug Release profile data of various 
formulations of Ibuprofen Sustained release tablets 
     The In vitro cumulative (%) drug release profile data of various 
formulations of Ibuprofen Sustained release tablets are shown in Table 27 and 
Figure 25. Based on the results Formulation(F7IB) only succeeded to allow a 
sustained release of drug. At the end of 24hrs highest drug release 99.41% and so 
it was considered as the optimized batch.    
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Comparison of selected formulations with marketed formulations 
Table 28: In vitro Dissolution profile of Marketed Ibuprofen SR formulations and 
Sustained release of Ibuprofen formulation (F7IB) 
 
Time (Hrs) 
%CDR ±S.D 
Marketed formulation Ibuprofen F7IB 
0 0 0 
2 4.86±0.33 11.72±0.34 
4 13.44±0.58 18.62±0.92 
6 58.86±0.43 24.53±0.30 
8 69.62±0.24 44.09±0.46 
10 80.16±0.48 64.32±0.17 
12 86.34±0.62 85.30±0.20 
14 89.69±0.41 88.17±0.06 
16 91.46±0.38 91.09±0.46 
18 94.57±0.54 92.97±0.26 
20 95.34±0.82 93.19±0.86 
22 97.23±0.74 94.97±0.74 
24 99.86±0.66 99.41±0.16 
Each value was an average of six determinations (n=6) ± S.D (standard Deviation) 
 
Figure 26: In vitro Dissolution profile of marketed Ibuprofen Sustained Release 
formulation and Sustained Release of Ibuprofen formulation (F7IB)  
 In marketed formulation 99.86% of release was observed within 24hrs and 
sustained release of Ibuprofen formulation (F7IB) 99.41% of release was observed 
within 24hrs. 
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Dissolution Kinetics 
Dissolution kinetics for Formulation 7 (F7IB) 
          The dissolution profiles of formulation F7 was subjected to various kinetic 
studies and are depicted in the following figure 27 to 30.  
Table 29: Drug release kinetic models for Ibuprofen sustained release tablets of 
Formulation(F7IB) 
Log T T %DR 
REMAIN 
 DR 
% 
LOG 
CUMU 
DR 
SQRT  T LOG % DR 
0.0 0 0.00 100 2 0.00 0.00 
0.3 2 4.09 95.91 1.98 1.41 0.61 
0.6 4 16.34 83.66 1.92 2.00 1.21 
0.8 6 24.32 75.68 1.88 2.45 1.39 
0.9 8 44.23 55.77 1.75 2.83 1.65 
1.0 10 54.90 45.1 1.65 3.16 1.74 
1.1 12 60.89 39.11 1.59 3.46 1.78 
1.1 14 74.33 25.67 1.41 3.74 1.87 
1.2 16 81.24 18.76 1.27 4.00 1.91 
1.3 18 92.97 7.03 0.85 4.24 1.97 
1.3 20 93.19 6.81 0.83 4.47 1.97 
1.3 22 94.97 5.03 0.70 4.69 1.98 
1.4 24 99.41 2.59 0.41 4.90 1.99 
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Figure 27: Zero order release kinetics F7IB 
 
 
Figure 28: First order release kinetics F7IB 
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Figure 29: Higuchi release kinetics F7 
 
Figure 30: Korsmeyer release kinetics F7IB 
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Table 30: Release kinetics data optimized Ibuprofen Sustained  
release tablet(F7IB) 
Formulation Model R2 Slope K 
F7IB 
Zero Order 0.9589 4.521 2.5844 
First Order 0.9401 0.0675 2.214 
Higuchi Model 0.9312 0.0383 1.0078 
Korsmeyer Model 0.9546 1.2371 0.4048 
 
 
 The In vitro release data of F7IB was fitted with various kinetics 
equations. From the table (30), it was shown that the regression coefficient 
[r2=0.9589] value was more in Zero order and Korsmeyer model [r2=0.9546]. 
 The value of ‘n’ was found to be 0.4048 which indicates that the drug 
release follows Fickian diffusion. 
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STABILITY STUDY  
 After storage the formulation was analysed for various parameters, results 
are showed in Table 31. 
Table 31: Stability study of best formulation F7IB 
Characteristic Initial 1st Month 2st Month 3st Month 6st Month 
Appearance White No change No change No change No change 
Texture Smooth Smooth Smooth Smooth Smooth 
Drug 
content(%) 
99.80±0.48 99.5±0.45 99.04±0.62 98.89±0.45 98.79±0.54 
%of Drug 
release 
97.41 ±0.16 97.23±0.34 96.45±0.22 96.24±0.43 96.01±0.42 
                       All the values are expressed as mean ±SD, n=3 
 From the table 31, there was no visible changes in the appearance of the 
formulation [F7IB], and the drug content and dissolution profile of the optimized 
formulation was related to the initial reference.  
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SUMMARY AND CONCLUSION 
           The objective of the present study was developed as sustained release 
tablets of Ibuprofen by solid dispersion technique. The results of FTIR study and 
DSC study confirmed that there is no chemical interaction or no incompatibility 
between the drug and excipients. The solid dispersion technique would be an 
effective approach for increasing the solubility and increasing dissolution 
behaviour of poorly water soluble drug. The granules were evaluated for 
precompression parameters like Bulk density, Tapped density, Angle of repose, 
Carr’s index, Hausner’s ratio. 
          Ten formulations were fabricated using with suitable rate controlling 
polymers like HPMCK4MCR, HPMCK100MCR. The compressed tablets were 
evaluated for post compressive parameters like Weight variation, Friability, 
Hardness, Drug content, was within the Pharmacopoeial  limit. 
           The in vitro dissolution study was performed for various formulations and 
marketed formulation. Based on the results F7IB was shown highest drug release 
99.41% within 24hrs. Various formulations were subjected to various model 
dependent kinetics like Zero order, First order, Higuchi, Korsmeyer-peppas 
release kinetics. The release profile exhibiting maximum r2 value was found to 
obey that Fickian diffusion kinetics. It was observed F7IB was found to be Zero 
order release kinetics.  
            Stability study was conducted as per ICH guidelines and the results 
showed that there is no physical or chemical change. 
           It may be concluded that the sustained release tablets of Ibuprofen by solid 
dispersion technique may reduce the dosing frequency and improve the patient 
compliance.  
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
BIBLIOGRAPHY 
1.  Banker G.S. and Rhodes C.T. Modern Pharmaceutics, 4th edn., Marcel 
 Dekker, Inc. New York, 2009, 167-184. 
2.  D.M.Brahmankar, and Sunil B. Jaiswal. ‘Bio pharmaceutics and 
Pharmacokinetics, A Treatise. 3rd edn., Vallabh Prakashan, New Delhi, 
2015, 400-460. 
3.  Aulton M.E.Pharmaceutics: The science of dosage form design, 
 3rdedition, Churchill Livingstone, New York, 2007, 355-359,483-498. 
4.  Vyas S.P and Khar R.k. Controlled Drug Delivery, Concepts and 
Advances, Vallabh Prakashan, 1st edn., New Delhi,2002,97-151. 
5.  Jithan A. Oral Drug Delivery Technology, Pharma Book Syndicate, New 
 York, 2007, 176-183. 
6. Navin Dixit, Sheo Dutt Maurya, Bhanu P.S.Sagar. Sustained Release 
 Drug Delivery System. Ind J Res Pharm Biotech. Vol1(3), 2013;  
 pp.305-310. 
7.  Manavalan R. and Ramasamy S. Physical Pharmaceutics: Accelerated 
 Stability Testing, 2nd edn., Vignesh Publisher, India, 2001, 288-299. 
8.  Subramanyam C.V.S. Text Book of Physical Pharmaceutics, Vallabh 
 Prakashan, New Delhi, 2009, 22-228. 
9. Bentley’s, Rawlins EA, Textbook of Pharmaceutics, Eighth Edn, 2003, 
 270-282. 
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
10. Robinson J.R and Lee V.L. Controlled Drug Delivery Fundamental and 
Application, 2nd  edn., Revised and Expanded, Marcel Dekker, Inc, New 
York. 2009, 337, 373-414. 
11. Martin A, Bustamante P, Chun AHC. Physical Pharmacy. 4th edn., New 
Delhi:BI Waverly Pvt.Ltd; 1994; pp. 465-466. 
12.  Shargel L. and Andrew B.C.Y. Applied Bio pharmaceutics and 
Pharmacokinetics, 5th edn., Singapore, 2005, 515-548. 
13.  Chio WL, Riegelman S. Pharmaceutical applications of solid dispersion 
systems.   J. Pharm. Sci. 1971; 60:1281-1302. 
14.  Swarbrick, Baylan. Encyclopedia of pharmaceutical technology. 2ndEd, 
Vol-1, 2002. Marcel Dekker Inc, pp.641-647. 
15. Kala H, Dittgen M. Solid dispersion technique for controlling drug 
release and absorption. Eastern Pharmacist 1995; 3:141. 
16.  Leunner.C, Dressman.J. Improving drug solubility for oral delivery 
using solid dispersions. Eur J Biopharm 2000; 50:47-60. 
17. Goracinova K, Kilsarova L, Simov A, Fredro Kumbaradzi E, 
Petrusevska-Tozi L. Preparation, physical characterisation, mechanisms 
of drug/polymer interactions and stability studies of controlled release of 
solid dispersion granules containing weak solid dispersion granules 
containing weak base as active substance. Drug Dev Ind Pharm. 1996; 
22(3): pp.255-262. 
18.  Kimia Fazaeli Kahkeshan, Ladan Akbarpour Nikghalb, Gurinder 
Singh, Gaurav Singh, Solid dispersion: Methods and Polymers to 
increase the solubility of poorly soluble drugs, Jr App Pharm Sci. Vol-2, 
2012, pp 170-175. 
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
19. Craig DQM. The mechanisms of drug release from solid dispersions in 
water soluble polymers. Int J Pharm. 2002; 231(2): 131-144.   
20. Sharma D.K, Joshi S.B. Solubility enhancement strategies for poorly 
water-soluble drugs in solid dispersion, a review. Asian J. Pharm. 2007; 
1(1), pp.9-19. 
21. Wagner W, Khana P, Furst DE. Non-steroidal anti-inflammatory drugs, 
disease modifying anti-inflammatory drugs, disease modifying anti 
rheumatic drugs, non-opioid analgesics and drugs used in Gout.In: 
Katzung BG editor. Basic and clinical pharmacology. 9th edn., McGraw 
hill Booston, 2004, pp.585. 
22. Tripathi K.D. Essential of Medical Pharmacology, 5th edn., Jaypee 
Brother’s Medical Publishers Ltd., 2003, 167-183. 
23. Rang A.P., Dale M.M. and Ritter J.M. Pharmacology, 4th edn., Churchil 
 Livingstone, London, 2001, 225-246. 
24. The Indian Pharmacopeia. Vol-1,II, and III, the Controller of 
 Publication, New Delhi, 2007, 63-65. 
25.  The British Pharmacopoeia. Vol-I and II, London, 2009, 78-82. 
26. U.S.P (United States Pharmacopoeia) 2011, Vol 3. 
27. Raymond C Rowe, Paul J Sheskey and Marian E Quinn.  Handbook of 
Pharmaceutical Excipients, 6th edn., Pharmaceutical Press and the 
American Pharmaceutical Association, London, 2009, 185, 210, 326, 364, 
404, 581.  
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
28.  Ansel H.C, Allen L.V and Popovich N.G. Pharmaceutical Dosage Forms 
and Drug Delivery System. 8th edn., Lippincott Williams and Wilkins, 
New Delhi, 2009, 78-82. 
29. Meka Anand Kumar, M.Kranthi Kumar, Dr.P.K.Lakshmi, and 
V.S.Giri Prasad. ‘Development and evaluation of solid dispersion 
formulated Ibuprofen tablets using Cyclo Dextrins as carrier’. Int J 
Pharm Res Del. Vol3 (11), 2011; pp. 93-101. 
30.  Gul Majid Khan ,Abdul Wahab, and Amjad Khan. ‘Preparation and 
evaluation of Solid Dispersions of Ibuprofen using Glucosamine HCL as a 
carrier’. Brt Jr of Ph Res 3(4): 2013; pp.722-733. 
31. Rupali S.Joshi, Nilima S. Pawar, Sameer S.Katiyar, Devendra B.Zope 
and Amol T.Shinde. ‘Development and validation UV spectrophotometric 
methods for simultaneous estimation of Ibuprofen in pure and tablet 
dosage form’. Der Pharmacia Sinica. Vol 2(3), 2011; pp. 164-171. 
32. Hapse S.A, Kadaskar P.T, and Shirsath A.S. ‘Difference 
spectrophotometric estimation and validation of Ibuprofen from bulk and 
tablet dosage form’. Der Pharmacia Lettre,     Vol 3(6), 2011; pp.18-23. 
33. Yousry M. Issa, Sayed I.M.Zayed, and Ibrahim H.I.Habib. 
‘Simultaneous determination of ibuprofen and paracetamol using 
derivatives of the ratio spectra method’. Arabian Journal of Chemistry 
(2011) 4; pp. 259-263. 
34. Lieberman H.A., Lachman L. and Schwartz J.B. Pharmaceutical 
Dosage Forms: Tablets Vol-Ⅰ and Ⅲ, Revised and Expanded, 2nd edn., 
Marcell Dekker, New York. 1999, 131-245,199-213. 
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
35.  Cooper J and Gunn C, Powder flow and compaction, In: Caroter SJ, eds. 
Tutorial Pharmacy, New Delhi, India: CBS Publishers and Distributors, 
1986, 211-213. 
36.  Lachman L and Lieberman HA, The Theory and Practices of Industrial 
Pharmacy, CBS Publication, New Delhi, 2009, 280-340. 
37. James I. Wells, (1987) Pharmaceutical Preformulation: The 
Physicochemical Properties of Drug Substances, John Willy Publication. 
38. Dabbagh MA, Taghipour B. Investigation of solid dispersion technique 
in improvement of physicochemical characteristics of Ibuprofen powder. 
Iran J Pharm Sci. 2007; 3:69-76. 
39.  Hugo Almeida, Maria Helena Amaral and Paulo Lobao. ‘Prolonged-
release solid dispersions of Ibuprofen. J App Pharm Sci. 02(06); 2012; 
pp.67-70. 
40. R.Margret chandira, Debjit Bhowmik, Rahul Yadav, B.Jayakar, and 
K.P.Sampanth Kumar. ‘Formulation and evaluation the oral tablets 
Ibuprofen. TPI Journal Vol.1 No.9, 2012; pp. 32-43. 
41. M.M.Gupta, Patel Mitul G, Patel Nimesh S, and Madhulika Kedawat. 
‘Enhancement of dissolution rate of Ibuprofen by preparing solid 
dispersion using different methods’. Int Jr  Pharm Sci. Vol 3, 2011; pp. 
204-206. 
42. Skoog D.A.Holler F and Niemans. Principles of Instrumental Analysis. 
5th edn., Thomson Asta Pvt. Limited, Singapore, 1966; pp.410-413. 
43.  Silverstein R.M and Webster F.X. Spectrometric identification of 
 organic compound, 6th edn., India, 2003; pp.79-143. 
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
44. Higuchi T and Connors K.A. Advanced analytical chemical 
 Instrumentation, 1965;4;117. 
45. Jitendra C.Shah, Ashwini deshpande. Kinetic modelling and 
comparison of in vitro dissolution profiles. World Jr Pharm Sci, 2014, 
vol2 (4), pp: 302-309.  
46. Suvakanta D, Naraimha M.P.Lilakanta N. and Chowdhry P. Kinetic 
Modelling on Drug Release from drug delivery systems, Acta Poloniae 
Pharmaceutical Drug Research, 2010; 67(3),pp.217-233. 
47. Abhik Kar, and Abdul Baquee Ahmed. ‘Enhancement of solubility and 
dissolution of Ibuprofen by solid dispersion technique and formulation of 
sustained release tablets containing the optimised batch of solid 
dispersion’. Int J Curr Pharm Res, Vol 9, 37-44. 
48. Madhuri Newa, Krishna H. Bhandari, Jung-Ae Kim, Bong-Kyu Yoo, 
Han-Gon Choi, and Chul-Soon Yong. ‘Preparation and evaluation of fast 
dissolving Ibuprofen Polyethylene Glycol 6000 Solid Dispersions’. Drug 
Delivery. 15:355-388,2008. 
49.  V.D.Sundhar, M.Madhavi Latha, S.Nandha Kumar, M.D.Dhana 
Raju. ‘Design and evaluation of sustained release tablets containing solid 
dispersion of Ziprasidone hydrochloride’. Int J Pharm Tech Res. 
Vol.6(3), 2014; pp.959-968. 
50. Suja C Jayan, Navaneet Krishna Manoj, Neethu Chacko, and 
Sheena.K.K. ‘Formulation and evaluation of Ibuprofen tablets using gum 
of Anacardium Occidentale as binding agent’. AJPCT [2][1][2014]; 
pp.013-023. 
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
51. Sachin K.Gawai, Subhah V. Deshmane, R.N.Purohit, Kailash R 
Biyani.’ In vivo-In vitro evaluation of solid dispersion containing 
Ibuprofen’. Amer Jr Advan Drug Deliv. 1[1], 2013; pp.066-072. 
52.  M.Sunitha Reddy, and T.Jyothirmayee. ‘Formulation and evaluation of 
Ibuprofen sustained release matrix tablets using Manlikara Zapota gum as 
a release retarding polymer’. Int J Inno Pharm Sci Res. 3(9), 2015; 
pp.1350-1361. 
53. Mohammed Omar, Anil Middha, and Dr.D.Ramakrishna. 
‘Formulation and in vitro evaluation of immediate release tablets of 
Fenofibrate solid dispersions by different techniques’. Int J of Pharmacy 
and Analytical Research. Vol4 (4), 2015; pp. 468-477. 
54. Koh PT, Chuah JN, Taleker M, Gorajana A, Garg S. ‘Formulation 
development and dissolution rate enhancement of Efavirenz by solid 
dispersion containing poorly water-soluble drugs’. Eur J Pharm 
Biopharm. 2013; pp.799-813. 
55. Bhawandeep Gill, Tejvir Kaur, Sandeep Kumar, and GD Gupta. 
‘Formulation and evaluation of Glimepiride solid dispersion tablets’. 
Asian Journal of Pharmaceutics. 2010; pp.212-218. 
56. Joshi HN, Tejwani RW, Davidovich M, Saharabudhe VP, Jemal M, 
Bathala MS. Bioavailability enhancement of a poorly water-soluble drug 
by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int J 
Pharm 2004, 251-269. 
57. M.Gopal Rao, R. Suneetha, P.Sudhakara Reddy and T.K.Ravi. 
‘Preparation and evaluation of Solid dispersions of Naproxen’. Int Jr 
Pharm Sci, 2005, 26-29. 
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
58. Jagdale SC, Patil SA, Kuchekar BS, Chanbukswar AR. ‘Preparation 
and characterization of Metformin Hydrochloride Compritol 888 ATO 
Solid dispersion’. J Young Pharmacists. Vol 3, 2011; pp.197-204. 
59. Logananthan, S., Marimaran, S.,Rajasekaran, A., Reddy, M.V.P. and 
Sulaiman, A. The effect of solid dispersions on (solubility) dissolution 
rate of Ibuprofen. The Eastern Pharmacist. 2000;XLIII (513), 115-116. 
60. Rawar S, Jain SK. Rofecoxib-beta-cyclodextrin in inclusion complex for 
solubility enhancement. Pharmazie 2003; 58: 639-641. 
61. Chowdari KPR, Srinivas L. Physical stability and dissolution rate of 
Ibuprofen suspension formulated employing solid dispersion. Indian J 
Pharm Sci.2000; 62: 253-256. 
62. Aftab Modi, and Pralhad Tayade, Enhancement of dissolution profile by 
solid dispersion technique, AAPS Pharm Sci Tech. 2006; 7(3), 68. 
63. Sakina Sultana and AHM Salfuddin. Review article: Solid dispersion 
currently practiced in pharmaceutical field. Int Jr Advan Res Tech. Vol 
5, 2016; pp.171-175. 
64.  Kala H, Dittgen M. Solid dispersion technique for controlling drug 
release and absorption. Eastern Pharmacist 1995; 3:141.  
65.  Nagarsenkar M.S, Rane M.S. Design and Evaluation of Solid 
Dispersions of weakly Basic Drugs for Controlled Release. Ind J Pharma. 
2002.   
66. Mohan Varma M and Satish Kumar P. ‘Formulation and evaluation of 
Gliclazide Tablets Containing PVP-K30 and Hydroxy propyl-β-
Cyclodextrin Solid Dispersion’. Int J Pharm Sci. 2012:5(2); pp.1706-
1719.   
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
67. Anusha Pagadala, Madhuri Asiniparthi and Vaidehi Donti. 
‘Formulation and evaluation of solid dispersion of Glimepiride in to 
sustained release’.Glob J Pharmaceu Sci. 1(2), 2016; pp.01-05. 
68. Syed Shariff Miyan, Mohamed Khaleel, Vazir Ashfaq Ahamed and 
Mohamed Yakhoob H. “Design and Development of fast Dissolving 
Tablets of Gliclazide by Solid Dispersion Technique”. Int J Pharm Chem 
Bio Sci. 2012; 2(3), pp.242-250.  
69.  S.L.Neha, Neelam Singh, and Mohd Yasir. “Sustained release solid 
dispersion of Metoclopramide HCL: formulation, evaluation and 
pharmacokinetic studies”. Jr App Pharm Sci 2015; Vol 5(03),  
pp. 055-065. 
70. Kenechukwu FC,  Ofokansi KC,  Ezugwu RO, Reginald Opara J, 
Agbo CP, Attama AA. ‘Formulation, Characterization and in vivo 
Evaluation of Ibuprofen-PEG 8000 solid dispersion systems’. Ind Jr 
Novel Drug Deliv. 9[3], 2017; pp.197-206. 
71. Jani Rupal, Jani Kaushnal, Setty C. Mallikarjuna, Patel Dipti. 
‘Preparation and evaluation of solid dispersions of Aceclofenac’. Int J 
Pharm Sci Drug Res. 2009;    pp. 32-35.  
72. Fayeza Tahseen A.B.Gangurde. ‘ Formulation development and In-vitro 
evaluation of sustained release tablets of Carvediol solid dispersion’. Int J 
Pharm Res Alli Sci. Vol 3, 2014; pp.52-61. 
73. S Kumar, Satish Kumar Gupta. ‘Preparation and evaluation of solid 
dispersions of Aceclofenac for the improvement of Dissolution rate’. J 
Chronother Drug Deliv. Vol 6,2015:pp.37-40. 
Bibliography 
 
 
 
Formulation and Characterization of Ibuprofen Sustained Release  
Tablets by Solid Dispersion Technique  
74. Ganesh Chaulang, Kundan Patil, Dhananjay Ghodke, Shagufta Khan 
and Pramod Yeole.’Preparation and Characterization of Solid Dispersion 
Tablet of Furosemide with Crospovidone’. Research J Pharm and Tech. 
1(4), 2008; pp.386-389. 
75. S.K Swain, Ch.Niranjan Patra, J.Sruti, and M.E. Bhanoji Rao. 
‘Design and evaluation of sustained release solid dispersions of Verapamil 
Hydrochloride’. Int J Pharm Sci Nanotech. Vol 3, 2011; pp.1252-1262. 
76. Samba Moorthy.U, Madan Mohan Kumawat, Rohit Reddy.T, 
Someshwar.K, Kumaraswamy.D. ‘Formulation of sustained release of 
solid dispersions of Verapamil Hydrochloride using Ethyl cellulose and 
Eudragit-RSPO. Int J Pharm Sci. Vol 3, 2010; pp.116-122. 
77.  Kosika Sandeep. ‘Formulation and evaluation of sustained release tablets 
from solid dispersion of Glipizide’. Int J Advan Res Found. Vol 4, 2017; 
pp.1-12.  
78. Patil SA, Kuchekar BS, Chanbukswar AR, Jagdale SC. ‘Formulation 
and Evaluation of Extended-Release Solid Dispersion of Metformin 
Hydrochloride’. J Young Pharm.Vol 2(2), 2010; pp.121-129.   
79. K.Arun Prasad, Narayanan N, Rajalakshmi G. ‘Preparation and 
evaluation of solid dispersion of Terbinafine hydrochloride’. Int J  Pharm 
Sci Rev and Res. 2010; pp.130-134. 
80. Rajeshree Panigrahi, Behera S P and Murthy P N. ‘Enhancement of 
solubility of Gliclazide by Solid Dispersion’. Intl J Pharm Tech 
Res.2011; 3(2): pp.1118-1124. 
81. Carstensen J.T, and Rhodes C.T. Drug stability principles and practices, 
3rd edn., Marcel Dekker, Int New York, 2008; pp.415-481. 
